Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1617srh
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS	3	Feb 06	Engineering Information Encompass files have new names
NEWS	4	Feb 16	TOXLINE no longer being updated
NEWS	5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS	6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS	7	May 07	DGENE Reload

NEWS EXPRESS	May 23 CURRENT WINDOWS VERSION IS V6.0a, CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP), AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:06:39 ON 01 JUN 2001

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 13:06:44 ON 01 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 30 MAY 2001 HIGHEST RN 339046-06-9
DICTIONARY FILE UPDATES: 30 MAY 2001 HIGHEST RN 339046-06-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

```
=> s famotidine/cn
L1            1 FAMOTIDINE/CN

=> s ranitidine/cn
L2            1 RANITIDINE/CN

=> s cimetidine/cn
L3            1 CIMETIDINE/CN

=> s nizatidine/cn
L4            1 NIZATIDINE/CN

=> s tranexamic acid/cn
L5            1 TRANEXAMIC ACID/CN

=> s cetraxate/cn
L6            1 CETRAXATE/CN

=> s erythritol/cn
L7            1 ERYTHRITOL/CN

=> s xylitol/cn
L8            1 XYLITOL/CN

=> s mannitol/cn
L9            2 MANNITOL/CN

=> s sorbitol/cn
L10           1 SORBITOL/CN

=> fil medline caplus embase biosis uspatfull wpids
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                           39.24      39.39

FILE 'MEDLINE' ENTERED AT 13:09:14 ON 01 JUN 2001

FILE 'CAPLUS' ENTERED AT 13:09:14 ON 01 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:09:14 ON 01 JUN 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:09:14 ON 01 JUN 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 13:09:14 ON 01 JUN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 13:09:14 ON 01 JUN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

=> s l1-l6 or famotidine or ranitidine or cimetidine or nizatidine or
tranexamic acid or cetraxate
   4 FILES SEARCHED...
L11       78932 (L1 OR L2 OR L3 OR L4 OR L5 OR L6) OR FAMOTIDINE OR RANITIDINE
                OR CIMETIDINE OR NIZATIDINE OR TRANEXAMIC ACID OR CETRAXATE
```

```
=> s l7-l10 or ERYTHRITOL or xylitol or mannitol or sorbitol
L12     177663 (L7 OR L8 OR L9 OR L10) OR ERYTHRITOL OR XYLITOL OR MANNITOL
OR
               SORBITOL

=> fil reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      24.42      63.81

FILE 'REGISTRY' ENTERED AT 13:11:28 ON 01 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:   30 MAY 2001  HIGHEST RN 339046-06-9
DICTIONARY FILE UPDATES:  30 MAY 2001  HIGHEST RN 339046-06-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Structure search limits have been increased.  See HELP SLIMIT
for details.

=> s antacid
L13          8 ANTACID

=> FIL MEDLINE CAPLUS EMBASE BIOSIS USPATFULL WPIDS
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       4.11      67.92

FILE 'MEDLINE' ENTERED AT 13:11:50 ON 01 JUN 2001

FILE 'CAPLUS' ENTERED AT 13:11:50 ON 01 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:11:50 ON 01 JUN 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

FILE 'BIOSIS' ENTERED AT 13:11:50 ON 01 JUN 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 13:11:50 ON 01 JUN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 13:11:50 ON 01 JUN 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

=> s l13 or sodium bicarbonate or calcium carbonate or sodium dihydrogen
phosphate
   5 FILES SEARCHED...
L14     212225 L13 OR SODIUM BICARBONATE OR CALCIUM CARBONATE OR SODIUM
DIHYDRO
               GEN PHOSPHATE
```

```
=> s l11 and l12 and l14
L15         512 L11 AND L12 AND L14

=> s l11 (S) l12 (S) l14
L16          33 L11 (S) L12 (S) L14

=> dup rem l16
PROCESSING COMPLETED FOR L16
L17          33 DUP REM L16 (0 DUPLICATES REMOVED)

=> d ibib abs kwic tot

L17  ANSWER 1 OF 33  WPIDS COPYRIGHT 2001   DERWENT INFORMATION LTD
ACCESSION NUMBER:      2001-191490 [19]   WPIDS
CROSS REFERENCE:       2001-183037 [16]
DOC. NO. CPI:          C2001-057379
TITLE:                 Oral drug delivery composition comprises a drug
                       substance, sugar, and a gas generating component and
                       provides prolonged gastric retention.
DERWENT CLASS:         A96 B05
INVENTOR(S):           STANIFORTH, J N; TALWAR, N; TOBYN, M J
PATENT ASSIGNEE(S):    (RANB-N) RANBAXY LAB LTD
COUNTRY COUNT:         94
PATENT INFORMATION:

     PATENT NO   KIND DATE     WEEK      LA   PG
     ---------------------------------------------
     WO 2001010419 A1 20010215 (200119)* EN   46
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
            NL OA PT SD SE SL SZ TZ UG ZW
         W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM
            DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
            LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
            SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

APPLICATION DETAILS:

     PATENT NO   KIND                  APPLICATION      DATE
     ------------------------------------------------------------
     WO 2001010419 A1                  WO 2000-IB1083   20000801


PRIORITY APPLN. INFO: WO 1999-IB1386   19990804
AN   2001-191490 [19]   WPIDS
CR   2001-183037 [16]
AB   WO 200110419 A UPAB: 20010405
     NOVELTY - Oral drug delivery composition for prolonged gastric retention
     has a highly porous matrix, and comprises: at least one drug substance;
     sugar; and a gas generating component which is a combination of at least
     one thermostable and at least one thermolabile component.
          DETAILED DESCRIPTION - Oral drug delivery composition for prolonged
     gastric retention has a highly porous matrix, and comprises: at least one
     drug substance; sugar; a gas generating component which is a combination
     of at least one thermostable and at least one thermolabile component; and
     optionally auxiliary components. The composition maintains its
     hydrodynamic balance and physical integrity while the drug is released in
     the stomach.
          USE - The composition is used for the oral delivery of drugs,
     preferably selected from an antiulcer, analgesic, antihypertensive,
```

antibiotic, antipsychotic, anticancer, antimuscarinic, diuretic, antimigraine, antiviral, anti-inflammatory, sedative, antidiabetic, antidepressant, antihistamine, antiparasitic, antiepileptic, and/or lipid lowering drug (claimed).

ADVANTAGE - The composition selectively delivers drugs at gastric levels and in upper parts of the small intestine over an extended period of time. The composition contains a gas generating agent which generates a gas to form a highly porous matrix with good floating characteristics, and also generates a gas on contact with gastric fluid which helps retain the buoyancy of the dosage form in the stomach.

Dwg.0/0

TECH. . .

sedative, antidiabetic, antidepressant, antihistamine, antiparasitic, antiepileptic, and/or lipid lowering drug. The drug can be selected from enalapril, captopril, benazepril, lisinopril, **ranitidine**, **famotidine**, **ranitidine** bismuth citrate, diltiazem, propranolol, verapamil, carvedilol, nifedipine, acyclovir, ciprofloxacin, simvastatin, atorvastatin, pravastatin, lovastatin, selegiline, midazolam, fluoxetine, acarbose, buspirone, nimesulide, nabumetone,. . . nefazodone.

Preferred Gas Generator: The gas generating component comprises a sulfite, a carbonate or a bicarbonate salt, preferably ammonium bicarbonate, **calcium carbonate**, **sodium bicarbonate**, potassium bicarbonate, sodium glycine carbonate, sodium sulfite, sodium bisulfite, and sodium metabisulfite. The gas generating component comprises a gas couple. . . sugar is selected from saccharide and/or polyhydric alcohols, preferably sucrose, glucose syrup, corn syrup, fructose, lactose, dextrose, galactose, maltose, maltodextrin, **sorbitol**, **mannitol**, maltol, maltitol, **xylitol** and lactitol. The auxiliary component is selected from diluents, release retarding agents, inert oils, binding agents and spheronizing agents, preferably. . .

L17 ANSWER 2 OF 33 USPATFULL

ACCESSION NUMBER:	2000:156993 USPATFULL
TITLE:	Process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets and compositions obtained thereby
INVENTOR(S):	Bonadeo, Daniele, Varese, Italy Ciccarello, Franco, Via la Loggia Mezzovico, Switzerland Pagano, Aberto, L'Aquila, Italy
PATENT ASSIGNEE(S):	Elan Pharma International Limited, Dublin, Ireland (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 6149938	20001121	
APPLICATION INFO.:	US 1998-122037	19980723	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	CH 1997-1797	19970725

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Page, Thurman K.
ASSISTANT EXAMINER:	Berman, Alysia

LEGAL REPRESENTATIVE: Anderson, Kirsten A.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 563
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for making a granulate composition suitable to the preparation
of an oral solid form that can disintegrate rapidly inside the buccal cavity is provided as well as the granulate compositions and obtained.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD

		Am. .times. tbl 1000 mg		Am. .times. a batch 700 g (700 tbl)	
1	**Cimetidine**	50.0	mg	35.000	g
2	**Xylitol**	7.5	mg	5.250	g
3	Aerosil 2000	3.0	mg	2.100	g
4	Monoammonium glycyrrhizinate	0.3	mg	0.210	g
5	Aspartame. . . 7 Talc	5.08	mg	3.556	g
8	Simethicone antifoam	0.12	mg	0.084	g
9	Triethyl citrate	1.0	mg	0.700	g
10	**Xylitol**	831.0	mg	581.700	g
11	PEG 6000	20.0	mg	14.000	g
12	Citric acid crystals	19.0	mg	13.300	g
13	**Sodium bicarbonate**	19.0	mg	13.300	g
14	Raspberry flavor	25.0	mg	17.500	g
15	Magnesium stearate	5.0	mg	3.500	g
	TOTAL	1000,0	mg	700.000. . .	

L17 ANSWER 3 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 2000-271210 [23] WPIDS
DOC. NO. CPI: C2000-082720
TITLE: Quick release pharmaceutical composition for oral administration useful for treatment of acute and/or mild or moderate pain.
DERWENT CLASS: B05 B07
INVENTOR(S): BERTELSEN, P; HANSEN, N G; ITAI, S; RUCKENDORFER, H
PATENT ASSIGNEE(S): (NYCO-N) NYCOMED DANMARK AS
COUNTRY COUNT: 87
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000015195	A1	20000323	(200023)*	EN	88
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ UG ZW					
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW					
AU 9955045	A	20000403	(200034)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000015195	A1	WO 1999-DK480	19990910
AU 9955045	A	AU 1999-55045	19990910

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9955045	A	Based on	WO 200015195

PRIORITY APPLN. INFO: DK 1998-1143 19980910
AN 2000-271210 [23] WPIDS
AB WO 200015195 A UPAB: 20000516
NOVELTY - A quick release pharmaceutical composition for oral administration comprises a therapeutically and/or prophylactically active substance which has a solubility of at most about 0.1% weight/volume in 0,1N hydrochloric acid at room temperature.

DETAILED DESCRIPTION - The composition is based on a powder comprising the active substance. The powder has a particle size such that when subjected to a sieve analysis at least about 90%-99% passes through a 180 mu m. sieve. The powder is contacted with an aqueous medium to form a particulate composition which has a particle size such that when subjected to a sieve analysis at least about 50%-95%, passes through a 180 mu m sieve. When tested by a dissolution method using 0.07N hydrochloric acid as the dissolution medium the composition releases at least about 50% weight/weight of the active substance within the first 20 minutes of the test.

USE - The composition is useful for treatment and/or prophylaxis of acute and/or mild or moderate pain, particularly for fast relief of acute pain.

Dwg.0/3

TECH. . .
binders, disintegrants, fillers and diluents, particularly a filler having binding properties selected from lactose (e.g. Tabletose, Pharmatose), sugar derivatives (e.g. **mannitol, sorbitol**), **calcium carbonate**, tricalcium phosphate, calcium hydrogen phosphate (e.g.Di-Cafos, Di-Tab, Emcompress or Pharmacompress) (preferred) and mixtures of these. The filler having binding properties. . . 25 microm(preferably)-140 mum, preferably 10-80 microm, more preferably about 15-55 microm. The composition further comprises an alkaline substance, preferably an **antacid** or **antacid** -like substance such as sodium hydrogen carbonate, magnesium carbonate, magnesium hydroxide or magnesium metasilicate aluminate or mixtures of these. The mean particle size of the **antacid**-like substance as raw material is at the most a 20-250 microm, preferably about 80-150 microm, especially 100-120 microm. The particulate. . . an antidepressant, an opioid, a prostaglandine analog (e.g. misoprostol), a glucocorticosteroid, a cytostatic (e.g. methotrexate), a H2 receptor antagonist (e.g. **cimetidine, ranitidine**), a proton pump inhibitor (e.g. pantoprazole, omeprazole, lansoprazole) and/or an **antacid** or is paracetamol, penicillamine, sulfasalazine or and/or auranorfin.

Preferred drugs: The active substance has a pKa value at most 4.0-5.5.

The. . .

L17 ANSWER 4 OF 33 USPATFULL

ACCESSION NUMBER:	1999:141277 USPATFULL
TITLE:	Herb medicine extract-containing non-bleeding striped dentifrice composition
INVENTOR(S):	Baik, In Sub, Taejon, Korea, Republic of Lee, Jong Gi, Taejon, Korea, Republic of Cho, In Sik, Seoul, Korea, Republic of Park, Youn Woo, Taejon-shi, Korea, Republic of
PATENT ASSIGNEE(S):	Aekyung Industrial Co., Ltd., Seoul, Korea, Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5980870	19991109
APPLICATION INFO.:	US 1997-934544	19970919 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-507706, filed on 26 Jul 1995, now abandoned	
PRIORITY INFORMATION:	KR 1994-18058	19940726

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Rose, Shep K.
LEGAL REPRESENTATIVE:	Merchant, Gould, Smith, Edell, Welter & Schmidt
NUMBER OF CLAIMS:	5
EXEMPLARY CLAIM:	1
LINE COUNT:	609

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A herb medicine extract-containing non-bleeding striped dentifrice composition, consisting essentially of a striped dentifrice component and a base dentifrice component, each component comprising the following ingredients at the substantially same amount: a. an abrasive that has a BET surface area of 10 m.sup.2 /g or less and an average particle diameter of 1 to 30 .mu.m upon measurement by Coulter Counter method, and shows oil absorption (linseed oil, ml/100 g) of 50 or less; b. a binder selected from the group consisting of xanthan gum, carrageenan, sodium carboxymethylcellulose, and the mixtures thereof; c. an alkyl sulfonate of anionic surfactants; and d. a humectant, and said striped dentifrice component containing herb medicine extracts at an amount of 0.001 to 10% by weight, on the basis of dry solid substance. It is non-bleeding by virtue of the substantially same formulation in the two components and the herb medicine extracts allow the dentifrice composition to suppress the formation of plaque.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . ingredients, ingredients included in conventional toothpaste are included, and for these ingredients abrasives such as alumina, silica gel, precipitated silica, **Calcium carbonate**, Calcium monohydrophosphate and **Sodium bicarbonate**, humectants such as **sorbitol**, glycerin and polyethylene glycol, foaming agents such as Sodium lauryl sulfate, Sodium lauryl sarcosinate and Dodecylbenzene sulfonate, binding agents such. . . para-oxy methyl benzoate and para-oxy propyl benzoate, medicine ingredients such as Sodium fluoride, Sodium fluorophosphate, Allantoin, Zinc salt, vitamins, salts, **Tranexamic acid**, Strontium Chloride and Trichlon, flavors, pigments and pH controller are used. Other

compositions for oral cavity may be produced by. . .

L17 ANSWER 5 OF 33 USPATFULL
ACCESSION NUMBER: 1999:78358 USPATFULL
TITLE: Lubricants for use in tabletting
INVENTOR(S): Daher, Lawrence J., Elkhart, IN, United States
PATENT ASSIGNEE(S): Bayer Corporation, Morristown, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5922351	19990713
APPLICATION INFO.:	US 1993-127433	19930927 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-908527, filed on 29 Jun 1992, now patented, Pat. No. US 5424075 which
is a continuation of Ser. No. US 1991-676165, filed on 27 Mar 1991, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Kim, John
LEGAL REPRESENTATIVE: Burns, Doane, Swecker & Mathis, L.L.P.
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a number of new water soluble lubricants and lubricant formulations which facilitate the production of tablets. In particular calcium and potassium sorbates and micronized combinations of polyethylene glycol with calcium ascorbate or with trisodium citrate or mixtures thereof are useful as lubricants, particularly in tablet compositions containing ingredients where rapid dissolution in an aqueous environment is desired for activity or desired for aesthetic purposes. A method is provided for surface treating calcium sorbate with docusate sodium, Simethicone Emulsion, USP or with lecithin to provide particularly useful tablet lubricants. The above lubricant(s) and lubricant formulations have fewer limitations and improved functionality in comparison to standard lubricants presently known. In addition, the lubricant(s) provided may be used with known hydrophobic lubricants to decrease the amount of the hydrophobic lubricant required for lubrication.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD

mg./tab.	
396	Ibuprofen/Sodium Citrate, Granulation
114	**Ranitidine**/Sodium Citrate, Granulation
1600	**Sodium Bicarbonate**
1300	Citric Acid/**Mannitol**, Granulation
180	Calcium Sorbate, finely powdered
3590	Total

DETD

mg./tab.	
657	**Sodium Bicarbonate**
1264	Citric Acid/**Mannitol**, Granulation

228	**Ranitidine**/Sodium Citrate, Granulation
145	Comicronized anhydrous trisodium Citrate/Polyethylene Glycol (Example 5)
145	Comicronized calcium ascorbate/Polyethylene Glycol (Example 6)
2439	Total

L17 ANSWER 6 OF 33 USPATFULL

ACCESSION NUMBER:	1999:34054 USPATFULL
TITLE:	Fluoride ion sustained release preformed glass ionomer filler and dental compositions containing the same
INVENTOR(S):	Roberts, Thomas Arwel, Congleton, United Kingdom Miyai, Kozo, Nara, Japan Ikemura, Kunio, Joyo, Japan Fuchigami, Kiyomi, Kyoto, Japan Kitamura, Toshio, Uji, Japan
PATENT ASSIGNEE(S):	Shofu Inc., Kyoto, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5883153	19990316
APPLICATION INFO.:	US 1997-892766	19970715 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-525662, filed on 29 Sep 1995, now abandoned	
PRIORITY INFORMATION:	GB 1993-7777	19930415

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Merriam, Andrew E.C.
LEGAL REPRESENTATIVE:	Stevens, Davis, Miller, & Mosher, L.L.P.
NUMBER OF CLAIMS:	31
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT:	2429

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a fluoride-ion sustained release pre-formed glass ionomer filler comprising a powdery reaction product of polyalkenoic acid with a fluorine-containing glass, and a method of producing the same. There is also provided a dental composition containing the filler.

The fluoride-ion sustained release pre-formed glass ionomer filler is long capable of releasing fluoride ions in the presence of water without involving disintegration. The dental composition of the invention is useful particularly for prevention of dental caries and like trouble.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . gel, aluminosilicate, and zirconosilicate, which are known as silica-based abrasive materials; and dibasic calcium phosphodihydrate, dibasic calcium phosphoanhydride, calcium pyrophosphate, **calcium carbonate**, aluminum hydroxide, titanium dioxide, alumina, magnesium carbonate, tribasic magnesium phosphate, and zeolite, which are known as synthetic resin-based abrasive materials. Viscous wetting agents available for use include, for example, glycerine, **sorbitol**, propylene glycol, and polyethylene glycol; and caking agents available for use include, for example, sodium carboxymethyl cellulose, hydroxyethyl cellulose, carrageenan,. . . sodium copper chlorophyllin, aluminum lactate, berberine, hydroxamic acid and

derivatives thereof, dextranase, mutanase, amylase, polyvinyl pyrrolidone, epidihydrocholesterol, benzetonium chloride, dihydrocholesterol, **tranexamic acid**, trichlorocarbanilide, zinc citrate, Japanese angelica root (ligusticum root) extract, and extracts of clove, rosemary, golden flower, safflower, etc. Also, mention. . .

L17 ANSWER 7 OF 33 USPATFULL

ACCESSION NUMBER:	1998:122100 USPATFULL
TITLE:	Pharmaceutical compositions containing famotidine and aluminum hydroxide or magnesium hydroxide
INVENTOR(S):	Roche, Edward John, Paoli, PA, United States Decoteau, Susan, Mystic, CT, United States Freeman, Eleanor, Norristown, PA, United States
PATENT ASSIGNEE(S):	McNeil-PPC, Inc., Skillman, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5817340	19981006
APPLICATION INFO.:	US 1996-756080	19961125 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-264223, filed on 22 Jun 1994, now abandoned which is a continuation of Ser.
No. US 1992-983923, filed on 1 Dec 1992, now abandoned

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Cintins, Marianne M.
ASSISTANT EXAMINER:	Moezie, M.
LEGAL REPRESENTATIVE:	Leightner, Joseph F.; Woodrow, Hal Brent
NUMBER OF CLAIMS:	7
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT:	799

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid oral dosage form for the treatment of gastrointestinal disorders
comprising a therapeutically effective amount of a therapeutically effective amount of guanidinothiazole compound; and a therapeutically effective amount of an antacid wherein the pharmaceutical and an antacid
are separated by a barrier which is substantially impermeable to an antacid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD TABLE 1

A:	Aluminum hydroxide	200 mg
	Famotidine	10 mg
B:	Magnesium hydroxide	200 mg
	Famotidine	10 mg
C:	*Aluminum hydroxide/ Magnesium hydroxide blend	400 mg
	Famotidine	10 mg
D:	****Calcium carbonate**	500 mg
	Famotidine	10 mg

*This blend of antacid is cospray-dried with **sorbitol** and **mannitol**.

The **calcium carbonate was granulated with acacia gum.

DETD

Antacid Blend
Antacids (i.e. **Calcium Carbonate**)
500.0 mg
Colloidal SiO.sub.2 0.8 mg
(Peppermint) Flavor 3.4 mg
Magnesium Stearate 8.3 mg
Dextrates 183.0 mg
Famotidine Blend
Famotidine (Rotogranulated/Coated)
87.97 mg
Mannitol 257.80 mg
Microcrystalline Cellulose
29.99 mg
Aspartame 2.50 mg
Corn Starch 1.23 mg
Mg. Stearate 3.85 mg
Flavor (Peppermint) 1.50 mg
Dye/Pigment 0.12 mg

DETD

Antacid Blend
Antacid i.e. **Calcium Carbonate**
285.7 mg
Magnesium Hydroxide 250.0 mg
Microcrystalline cellulose
70.0 mg
Crosscarmellose sodium NF or
Sodium Starch Glycolate NF
40.0 mg
Famotidine Blend
Famotidine (Rotogranules
87.97 mg
coated to deliver 10 mg)
Mannitol NF 257.8 mg
Peppermint Flavor 1.60 mg
Microcrystalline Cellulose
29.99 mg
Asparatame 2.50 mg
Corn Starch 1.23 mg
Magnesium Stearate 3.85 mg
Dye/Pigment 0.12 mg

L17 ANSWER 8 OF 33 USPATFULL
ACCESSION NUMBER: 1998:95250 USPATFULL
TITLE: Granular product or tablet containing an effervescent system and an active pharmaceutical substance, as well as a method for its preparation
INVENTOR(S): Gergely, Gehard, Vienna, Austria
Gergely, Thomas, Vienna, Austria
Gergely, Irmgard, Vienna, Austria
Gergely, Stefan, Vienna, Austria
PATENT ASSIGNEE(S): Gergely, Gerhard, Vienna, Austria (non-U.S. individual)

	NUMBER	DATE	
PATENT INFORMATION:	US 5792473	19980811	
APPLICATION INFO.:	US 1996-620261	19960322	(8)
DOCUMENT TYPE:	Utility		

PRIMARY EXAMINER: Kishore, Gollamudi S.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 71
EXEMPLARY CLAIM: 1
LINE COUNT: 1315
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with this invention there is provided a granular product with an effervescent system which comprises acid-sensitive pharmaceutically active substances, such as, for example, betacarotene, cimetidine, ranitidine or cisapride, which is specially useful to prevent antacid action, having an acid-neutralizing capacity below about 5 meq, at a weight of about 1.6 to about 2.3 grams. The effervescent grains are made from carrier crystals of at least one solid, edible organic acid, preferably citric acid and/or tartaric acid, and are present as a granular product, separate from the pharmaceutically active substance, and are coated with at least one layer of a neutral substance which is soluble in water and/or alcohol and which is able to bring about a melting point depression of the acid grains at their surface, such as, for example, a water-soluble polymer, a polyalcohol, a carbohydrate and/or a hydrocolloid. A second coating contains at least a part of the alkali and/or alkaline earth carbonate or bicarbonate provided for the total dosage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . a solution 1, which has been prepared from 0.25 parts by weight of water and 0.20 parts by weight of **mannitol**, is aspirated in and distributed on the citric acid by mixing, whereupon 14.7 parts by weight of **sodium bicarbonate** and 3.2 parts by weight of aspartame are then added. Reaction is started with stirring and then drying is performed. . . 2.8 parts by weight of sodium carbonate are added. To this mixture is then added 17.3 parts by weight of **cimetidine**, 4.3 parts by weight of **mannitol**, 8 parts by weight of **sorbitol**, 0.9 parts by weight of flavoring, and 4 parts by weight of antifoaming agent particles prepared according to Example 1. . .

DETD TABLE 1

Cimetidine	2-30%	(corresponds to an effervescent tablet containing 50 to 600 mg of **cimetidine**)
Citric acid	30-60%	**sorbitol** 5-20%
Sodium bicarbonate	10-30%	**mannitol** 2-10%
Sodium carbonate	2-10%	simethicone 0.005-0.5%
Aspartame	1-4%	flavoring 0.1-3%

DETD To the effervescent grains thus prepared, 167 parts by weight of **ranitidine** hydrochloride, 125 parts by weight of **mannitol** plus 100.4 parts by weight of a granulated antifoaming agent (consisting of 100 parts by weight of **mannitol** and 0.4 parts by weight of simethicone) and the flavoring agent are added. This mixture is mixed for 15 minutes. . . of 60 to 80 seconds and an acid-neutralizing capacity of about 2 meq and contain (in percent by

weight) 6.8 **ranitidine** hydrochloride, 42.0 citric acid, 14.8 monosodium citrate, 20.0 **sodium bicarbonate**, 4.0 sodium carbonate, 2.0 sweeteners, 5.0 **mannitol**, 0.1 **sorbitol**, 4.0 granulated antifoaming agent (containing 0.016 dimethylpolysiloxane) and 1.2 flavoring.

DETD . . . as the first coating, a solution-which consists of 6 parts by weight of water and 4 parts by weight of **sorbitol** is distributed on the surface by stirring. Next, 222 parts by weight of **sodium bicarbonate** are made to react on the surface of the citric acid, and finally 80 parts by weight of sodium carbonate. . . . are screened to 1.5 mm, and then mixed for 10 minutes at 10 rpm with 167 parts by weight of **ranitidine** hydrochloride, 100 parts by weight of anti-foaming particles (containing 0.4 parts by weight of simethicone and 100 parts by weight. . . 65-70 sec, a hardness of 8, and an acid-neutralizing capacity of about 1.5 meq. The product contains no monosodium citrate. **Ranitidine** effervescent tablets having such a low acid-neutralizing capacity have not been disclosed to date.

DETD . . . to 60.degree. C., then two-thirds of a solution which consists of, with respect to the final mixture, 0.6% water, 0.18% **sorbitol**, and 0.12% trisodium citrate is applied. The solution is distributed for 5 minutes by mixing at 10 rpm. Then 16.2% of **sodium bicarbonate** and 2.9% of aspartame are added and anchored on the surface of the citric acid crystals by reaction on the. . . 50.degree. C., to 15 mbar. The basic effervescent granular product is screened to 1.5 mm and mixed with 11.0% of **ranitidine** hydrochloride, 6.5% of **mannitol**, 6.5% of anti-foaming particles plus 0.2% of flavoring, and pressed to tablets of 1.55 g, which have a disintegration time. . .

DETD

[wt %]	[pbw]	
40	1000	coarse citric acid
10	250	powdered citric acid
0.04	1	trisodium citrate
0.12	3	sorbitol
20	500	**sodium bicarbonate**
6	150	trisodium citrate, anh.
4	100	sodium carbonate
6.68	167	**ranitidine**-HCl
5	125	**mannitol**
4.02	100.5	**mannitol**/simethicone phase
4.14	103.5	flavor and sweeteners
100%	2500 pbw	

DETD

[wt. %]	[pbw]	
37	925	coarse citric acid
10	250	powdered citric acid
0.04	1	trisodium citrate
0.12	3	**sorbitol**
14	350	**sodium bicarbonate**
12	300	trisodium citrate, anh.
4	100	sodium carbonate
6.68	167	**ranitidine**-HCl
10	250	**mannitol**:
4.02	100.5	**mannitol**/simethicone phase
2.14	53.5	sweeteners and flavor

100% 2500 pbw

DETD

[%]	[pbw]	
35	875	coarse tartaric acid
9	225	powdered tartaric acid
0.22	5.5	**sorbitol**
30	750	**sodium bicarbonate**
4	100	sodium carbonate, anh.
6.68	167	**ranitidine**-HCl
7	175	**mannitol**
4.02	100.5	**mannitol**/simethicone phase
4.08	102	orange flavor "PAC"
100%	2500 pbw	

L17 ANSWER 9 OF 33 USPATFULL

ACCESSION NUMBER: 1998:9172 USPATFULL
TITLE: Oral composition
INVENTOR(S): Nishida, Yasukuni, Odawara, Japan
Morishima, Midori, Odawara, Japan
Ohta, Maimi, Odawara, Japan
Gomi, Tetsuo, Tokyo, Japan
Harada, Yoshihiro, Odawara, Japan
PATENT ASSIGNEE(S): Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5711937	19980127	
	WO 9500110	19950105	
APPLICATION INFO.:	US 1995-571914	19951227	(8)
	WO 1994-JP1019	19940624	
		19951227	PCT 371 date
		19951227	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-181970	19930628
	JP 1993-348108	19931224

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral composition is provided which is improved in antibody stability so that the antibody may satisfactorily exert its effect after long-term storage and has a pleasant feel on use. A flavor component selected from the group consisting of carvone, anethole, cineole, methyl salicylate, eugenol, ethyl butyrate, and cinnamic aldehyde, and l-menthol are blended in a weight ratio of from 1:9 to 8:2 in an oral composition containing an antibody selected from the group consisting of a serum antibody, egg yolk antibody and milk antibody.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD

Example 19: Dentifrice

Calcium hydrogen phosphate dihydride	50.0%
Sorbitol	10.0
Glycerin	10.0
Carrageenan	1.0
Sodium lauryl sulfate	1.0
l-menthol	0.3
Peppermint oil	0.6
Eugenol	0.03
Anethole	0.17
Saccharin	0.1
Ethanol	2.0
Dextranase	0.02
Anti-PAC goat milk antibody or	0.2
anti-Pg surface layer polysaccharide sheep serum antibody	
Water	balance
	100.0%

Example 20: Dentifrice

Silicic anhydride	30.0%
Glycerin	30.0
Sorbitol	20.0
Carboxymethyl cellulose	1.0
Sodiurn lauryl sulfate	1.2
l-menthol	0.1
Carvone	0.05
Spearmint oil	0.4
Peppermint oil	0.3
Saccharin	0.1
Ethanol	2.0
Sodium fluoride	0.1
Anti-PAC horse serum antibody or	0.1
anti-Pg whole cell horse serum antibody	
Water	balance
	100.0%

Example 21: Dentitrice

Aluminum hydroxide	45.0%
Sorbitol	20.0
Carrageenan	0.5
Carboxymethyl cellulose	1.0
Lauryl diethanolamide	1.0
Sucrose monolaurate	2.0
l-menthol	0.6
Peppermint oil	0.2
Cineole	0.4
Saccharin	0.1
Anti-PAc cow milk antibody	0.3
Water	balance
	100.0%

Example 22: Dentifrice

Aluminum hydroxide	45.0%
Sorbitol	20.0

Carrageenan	0.5
Carboxymethyl cellulose	1.0
Lauryl diethanolamide	1.0
Sucrose monolaurate	2.0
l-menthol	0.6
Peppermint oil	0.2
Cineole	0.4
Saccharin	0.1
Anti-Pg fimbriae horse serum antibody	0.2
Anti-Aa fimbriae horse serum antibody	0.2
Water	balance
	100.0%

Example 23: Dentifrice

Calcium hydrogen phosphate	45.0%
Carboxymethyl cellulose	1.0
Carrageenan	0.5
Sorbitol	35.0
Propylene glycol	3.0
Sodium N-lauroylmethyltaurine	0.5
Gelatin	1.0
Ethyl p-hydroxybenzoate	0.2
Saccharin sodium	0.1
l-menthol	0.6
Methyl salicylate	0.3
Sodium monofluorophosphate	0.7
Anti-PAC hen egg antibody or	0.4
anti-Av fimbriae egg antibody	
Water	balance
	100.0%

Example 24: Dentifrice

Aluminum hydroxide	40.0%
Sodium carboxymethyl cellulose	1.0
Carrageenan	0.5
Sorbitol	35.0
Propylene glycol	3.0
Sodium N-myristoylmethyltaurine	0.5
Peptide	1.0
Methyl p-hydroxybenzoate	0.2
Saccharin sodium	0.1
l-menthol	0.5
Peppermint oil	0.2
Cinnamic aldehyde	0.15
Spice mix flavor	0.05
Anti-PAC sheep serum antibody or	0.5
anti-Pi surface layer of polysaccharide sheep serum antibody	
Water	balance

	100.0%

Example 25: Dentifrice

Silicic anhydride	20.0%
Sodium carboxymethyl cellulose	1.0
Sorbitol	50.0
Polyethylene glycol	5.0
Sodium N-palmitoylmethyltaurine	0.5
Casein	1.0
Sodium p-hydroxybenzoate	0.2
Saccharin sodium	0.1
l-menthol	0.3
Cineole	0.1
Ethyl butyrate	0.01
Sodium fluoride	0.2
Anti-GTF hen egg antibody	0.3
Water	balance
	100.0%

Example 26: Dentifrice

Silicic anhydride	20.0%
Sodium carboxymethyl cellulose	1.0
Sorbitol	50.0
Polyethylene glycol	5.0
Sodium N-palmitoylmethyltaurine	0.5
Casein	1.0
Sodium p-hydroxybenzoate	0.2
Saccharin sodium	0.1
l-menthol	0.3
Cineole	0.1
Ethyl butyrate	0.01
Tranexamic acid	0.1
Anti-Fn whole cell hen egg antibody	0.3
Water	balance
	100.0%

Example 27: Mouthwash

Ethanol	20.0%
l-menthol	0.2
Peppermint oil	0.2
Eugenol	0.1
Cineole	0 05
Anethole	0.03
Saccharin	0.05
Lauryl diethanolamide	0.3
Chlorohexidine gluconate	0.01
Anti-GTF horse serum antibody or anti-Cr surface layer polysaccharide goat serum antibody	0.1
Water	balance
	100.0%

Example 28: Mouthwash

Sorbitol	10.0%

Ethanol	20.0
Sodium N-myristoyltaurine	0.5
Sucrose stearate	1.0
Peptide	0.5
Methyl p-hydroxybenzoate	0.1
Stevioside	0.1
l-menthol	0.2
Methyl salicylate	0.3
Cinnamic aldehyde	0.1
Ethyl butyrate	0.05
Dextranase	0.2
Sodium fluoride	0.2
Anti-Aa surface layer polysaccharide	0.2
hen egg antibody	
Water	balance
	100.0%

Example 29: Mouthwash

Sorbitol	10.0%
Ethanol	20.0
Sodium N-myristoyltaurine	0.5
Sucrose stearate	1.0
Peptide	0.5
Methyl p-hydroxybenzoate	0.1
Stevioside	0.1
l-menthol	0.2
Methyl salicylate	0.3
Cinnamic aldehyde	0.1
Ethyl butyrate	0.05
Dextranase	0.2
Cetyl pyridinium chloride	0.05
Anti-Bf whole cell	0.2
hen egg antibody	
Water	balance
	100.0%

Example 30: Mouthwash

Sorbitol	10.0%
Ethanol	20.0
Sodium N-stearoylmethyltaurine	0.5
POE (20) sorbitan monooleate	1.0
Collagen	0.5
Methyl p-hydroxybenzoate	0.1
Saccharin sodium	0.1
l-menthol	0.05
Carvone	0.1
Spearmint oil	0.3
Peppermint oil	0.3
Anti-PAC cow. . .	0.2
Cineole	0.1
Benzaldehyde	0.05
Sodium ascorbate	0.1
Anti-PAc goat milk antibody or	

	0.1
anti-Aa capsule goat milk antibody	
Water	balance
	100.0%

Example 32: Chewing gum

Gum base	43.9%
Calcium carbonate	2.0
Hydrolyzed starch	15.0
Sugar	29.0
Sucrose palmitate	1.0
Fructose	4.0
Aldose	3.0
l-menthol	0.6
Carvone	0.4
Fruit mix flavor	1.0
Anti-PAc hen egg antibody or	
	0.1
anti-Pg fimbriae hen. . .	

L17 ANSWER 10 OF 33 USPATFULL

ACCESSION NUMBER:	97:38184 USPATFULL
TITLE:	Oral composition
INVENTOR(S):	Shimada, Toshiya, Tokyo, Japan Mukasa, Kazuo, Konosu, Japan Gomi, Tetsuo, Tokyo, Japan Yokoo, Takao, Kasubake, Japan
PATENT ASSIGNEE(S):	Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5626837	19970506
APPLICATION INFO.:	US 1996-601831	19960215 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-284212, filed on 2 Aug 1994, now abandoned	
PRIORITY INFORMATION:	JP 1993-220646	19930812

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Rose, Shep K.
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
LINE COUNT:	732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In an oral composition comprising a cationic bactericide, either one or both of cyclodextrin and a water-soluble flavor obtained by extracting an oil-soluble flavor with an aqueous ethanol solution are blended. The composition allows the cationic bactericide to exert its activity to a full extent, presents a pleasant feel on use without any peculiar taste, and is stable during storage. The invention eliminates the use of anionic and nonionic surfactants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD

Example 1: Dental rinse

Chlorhexidine gluconate	
	0.05
Triclosan	0.005

Xylitol	15.0
Taumatine	0.05
Glycyrrhizin monogluconide	0.003
Branched cyclodextrin	0.03
Menthol	0.01
Strawberry flavor	0.005
Ethanol	5.0
Pure water	Balance
Total	100.0%

Example 2: Mouthwash

Benzethonium chloride	0.05
Sodium fluoride	0.05
Sorbitol (65%)	20.0
Acesulfam	0.005
Methylparaben	0.01
.beta.-cyclodextrin	0.01
Water-soluble spearmint oil 1)	0.5
Menthol	0.05
Methyl salicylate	0.005
Water-soluble spice mix oil 2)	0.05
Ethanol	15.0
Pure water	Balance
Total	100.0%

Example 3: Mouthwash

Cetyl pyridinium chloride	0.05
Tranexamic acid	0.05
Glycerin (85%)	9.0
Hernandulcin	0.05
Citric acid	0.05
Sodium citrate	0.3
Water-soluble peppermint oil 3)	0.5
Menthol	0.01
Ethanol	15.0
Pure water	Balance
Total	100.0%

Example 4: Liquid mouth. . . 0.05

Lysozyme chloride	0.05
Citric acid	0.05
Sodium acetate	5.0
Water-soluble strawberry oil 5)	1.0
Pure water	Balance
Total	100.0%

Example 6: Toothpaste

Benzalkonium chloride	0.05
Triclosan	0.005
Sodium fluoride	0.005
Calcium carbonate	50.0
Carrageenan	0.6
Sodium carboxymethyl cellulose	0.5
Glycerin (85%)	20.0
Vitamin E	0.003
Sodium chloride	0.5
Menthol	0.50

Water-soluble herb oil 6)
0.50
Anethole 0.1
Spicemix flavor 0.001
Spilanthol 0.003
Pure water Balance
Total 100.0%
Example 7: Toothpaste
Chlorhexidine hydrochloride
0.02
Cetylpyridinium bromide
0.05
Stannous fluoride 0.005
Azulene 0.001
Calcium hydrogen phosphate dihydrate
50.0
Carrageenan 0.8
Sodium carboxymethyl cellulose
0.6
Sorbitol (60%) 25.0
Propylparaben 0.01
Menthol 0.30
Water-soluble floral flavor 7)
0.50
Water-soluble star anise flavor 8)
0.3
Peppermint oil 0.02
.gamma.-cyclodextrin 0.02
Pure water Balance
Total 100.0%
Example 8:. . .

L17 ANSWER 11 OF 33 USPATFULL
ACCESSION NUMBER: 97:33775 USPATFULL
TITLE: Oral compositions of H2-antagonists
INVENTOR(S): Caldwell, Henry C., Ambler, PA, United States
Desai, Ashok J., Wilmington, NC, United States
PATENT ASSIGNEE(S): Applied Analytical Industries, Inc., Wilmington, NC, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5622980	19970422
APPLICATION INFO.:	US 1995-382602	19950202 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-288711, filed on 12 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-107126, filed on 17 Aug 1993, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Henley, III, Raymond
LEGAL REPRESENTATIVE: Bell, Seltzer, Park & Gibson
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides a pharmaceutical composition for the oral
administration of an H.sub.2 -antagonist. The composition includes an H.sub.2 -antagonist and a silicate taste-masking agent capable of forming an adsorbate complex with the H.sub.2 -antagonist wherein the

complex exhibits a non-bitter taste. The complex inhibits the release of
the H.sub.2 -antagonist in the oral cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD TABLE 2

Ingredients	% By Weight A	B	C	D
Nizatidine	5	--	--	--
Cimetidine	--	5	--	--
Ranitidine HCl USP	--	--	5.6	--
Famotidine	--	--	--	2
Magnesium Aluminum Silicate NF	25	25	25	10
Calcium Carbonate USP	5	5	5	5
Sodium Saccharin NF	.25	.25	.25	.125
Mannitol NF	Q.S.	Q.S.	Q.S.	Q.S.
Xylitol NF	Q.S.	Q.S.	Q.S.	Q.S.
Collodial Silicon Dioxide NF	1	1	1	1
Magnesium Stearate NF	1.5	1.5	1.5	1.5
Flavors	Q.S.	Q.S..	.	.

CLM What is claimed is:
. . . of an H.sub.2 -antagonist, wherein said composition exhibits a non-bitter taste, said composition comprising a non-bitter tasting adsorbate complex of **ranitidine** hydrochloride and magnesium aluminum silicate, a dissociation agent consisting of **calcium carbonate**, and an a flavoring agent selected from the group consisting of citric acid and **xylitol**.

L17 ANSWER 12 OF 33 USPATFULL
ACCESSION NUMBER: 97:7948 USPATFULL
TITLE: Cimetidine granules coated with a partially hydrogenated vegetable oil
INVENTOR(S): Chauhan, Sushil, SmithKline Beecham Corporation, Corporate Intellectual Property - U.S., UW2220, P.O. Box 1539, King of Prussia, PA, United States 19406-0939
France, Gordon, SmithKline Beecham Corporation, Corporate Intellectual Property - U.S., UW2220, P.O. Box 1539, King of Prussia, PA, United States 19406-0939
Buehler, John, SmithKline Beecham Corporation, Corporate Intellectual Property - U.S., UW2220, P.O. Box 1539, King of Prussia, PA, United States 19406-0939

	NUMBER	DATE	
PATENT INFORMATION:	US 5597844	19970128	
	WO 9412180	19940609	
APPLICATION INFO.:	US 1995-446708	19950714	(8)
	WO 1993-EP3272	19931122	
		19950714	PCT 371 date
		19950714	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-24855	19921127

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Henley, III, Raymond
LEGAL REPRESENTATIVE: Dinner, Dara L.; Venetianer, Stephen; Lentz, Edward T.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 366
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A non-aqueous, chewable composition for oral delivery of unpalatable drugs is provided. The composition contains the drug intimately dispersed or dissolved in a pharmaceutically acceptable lipid that is solid at room temperatures. The composition also has a matrix that contains a granulating agent for the total composition and a rapid dispersal agent and optionally additives such as buffering agents, flavoring agents, surfactants and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD

Ingredients	mg/tablet
Coated **Cimetidine** Granules (Example 2)	400
Alginic acid	500
Sodium Bicarbonate	170
Sorbitol	680
Pregelatinised Starch	30
Croscarmellose Sodium Type A	60
Lactose	330
Aspartame	5
Sodium Saccharin	5
Magnesium Stearate	35
Flavours	50
Total	2265

L17 ANSWER 13 OF 33 USPATFULL
ACCESSION NUMBER: 96:20929 USPATFULL
TITLE: Coating method
INVENTOR(S): Nishii, Hiroyuki, Takatsuki, Japan
Kobayashi, Masaru, Takatsuki, Japan
Toya, Kazutoshi, Nagaokakyo, Japan
Uchiyama, Nobuo, Toyonaka, Japan
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Osaka, Japan
(non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5498447	19960312	
	WO 9321893	19931111	
APPLICATION INFO.:	US 1994-331482	19941104	(8)
	WO 1993-JP543	19930427	
		19941104	PCT 371 date
		19941104	PCT 102(e) date

	NUMBER	DATE

PRIORITY INFORMATION:	JP 1992-143362	19920507
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Beck, Shrive	
ASSISTANT EXAMINER:	Maiorana, David	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	364	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A coating method which is characterized in that, when the surfaces of solid particles kept flowing are spray-coated with a thermally melted wax, a two-fluid nozzle adapted to mix a thermally melted wax with a heating gas in and eject the resultant mixture from one flow passage and eject a heating gas from the other flow passage is used, the two-fluid nozzle having spray ports of a diameter of 1.5 to 5.8 mm, and the two-fluid nozzle having no needle valve. According to this method, the use of an organic solvent for melting wax is omitted, and complicated operations for pulverizing a wax and for thermally melting the wax powder after it has been deposed on solid particles are not required. This method can also prevents clogging of the nozzle, powdering of the melted wax and forming of agglomerated solid, and permits simple and easy production of sustained release preparations and preparations for masking materials of unpleasant and bitter tastes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . conventional carrier used in the preparation of solid preparations, for example, fillers such as corn starch, potato starch, lactose, sucrose, **mannitol**, talc, kaolin, calcium sulfate, **calcium carbonate**, etc.; lubricants such as magnesium stearate, calcium stearate, etc.; disintegrants such as carboxymethyl cellulose calcium, low-substituted hydroxypropyl cellulose, crystalline cellulose,. . . antihistaminics, cardiovascular agents, tranquilizers, antibiotics (e.g. indomethacin, ibuprofen, acetaminophen, caffeine, isopropylantipyrine, carbetapentane citrate, phenylpopanolamine hydrochloride, chloropheniramine maleate, diphenylpyraline hydrochloride, sulpiride, **cimetidine**, isothipendyl hydrochloride, propranolol hydrochloride, cephalexin, bencyclane fumarate, lithium carbonate, etc.), insecticides (e.g. allethrin, fenitrothion, phenothrin, etc.), feed additives (e.g. biotin,. . .

L17 ANSWER 14 OF 33 USPATFULL

ACCESSION NUMBER:	95:80289 USPATFULL	
TITLE:	Gastrointestinal anti-irritant composition comprising sucralfate and methods of use	
INVENTOR(S):	McCullough, Ricky W., 165 Crary St., Providence, RI, United States 02903	
	NUMBER	DATE
PATENT INFORMATION:	US 5447918	19950905
APPLICATION INFO.:	US 1994-205383	19940304 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-77715, filed on 17 Jun 1993, now abandoned which is a division of Ser. No. US 1992-919740, filed on 27 Jul 1992, now abandoned	

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Robinson, Douglas W.
ASSISTANT EXAMINER: Osoteo, Maria Luisa
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprising sucralfate and one or more anti-acid epigastralgic relieving agents in a weight ratio of between 0.5:1.0 to 1.3 sucralfate to anti-acid epigastralgic relieving agent and a method of using the composition for relieving symptoms of gastrointestinal mucosal irritation in mammals. The composition may be either in liquid or solid dose form having a combined composition weight percentage of 10-30% per 5 milliliter volume of liquid or 40-85% per solid unit dose form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . ml

Aluminum Hydroxide	400-500
Magnesium Hodroxide	400-500
Sucralfate [a poly[phosphoryl/ sulfon]-ated carbohydrate]	250-500
.+-.Simethecone	40-80
Potassium Bicarbonate USP	40-60
Methyl Paraben USP	5-10
Propyl Paraben USP	5-10
Sodium Saccharin	3.0-5.0
Sorbitol USP	200-350
Flavor	q.s.
Water	5000

EXAMPLE 4
Formulations of Liquid Magaldrate/Sucralfate

	mg/5 ml
Magaldrate	500-1100
Sucralfate [a poly[phosphoryl/ sulfon]-ated carbohydrate]	250-500
.+-.Simethecone	40-80
Methyl Paraben USP	5-10
Propyl Paraben USP	5-10
Sodium Saccharin	3.0-5.0
Sorbitol USP	200-350
Flavor	q.s.
Water	5000

EXAMPLE 5
Formulations of Liquid Magnesium Alginate/Aluminum Hydroxide/Sucralfate

	mg/5 ml
Magnesium Alginate	500-600
Aluminum Hydroxide-Magnesium Carbonate Gel	150-300
Sucralfate [a poly[phosphoryl/	250-500

sulfon] -ated carbohydrate]

.+-.Simethecone	40-80
Potassium Bicarbonate USP	40-60
Methyl Paraben USP	5-10
Propyl Paraben USP	5-10
Sodium Saccharin	3.0-5.0
Sorbitol USP	200-350
Flavor	q.s.
Water	5000

EXAMPLE 6

Formulations of Liquid **Calcium Carbonate**/Magnesium Carbonate/Sucralfate

	mg/5 ml
Calcium Carbonate	400-500
Sucralfate [a poly[phosphoryl/ sulfon]-ated carbohydrate]	250-500
.+-.Simethecone	40-80
Methyl Paraben USP	5-10
Propyl Paraben USP	5-10
Sodium Saccharin	3.0-5.0
Sorbitol USP	200-350
Flavor	q.s.
Water	5000

EXAMPLE 7

Formulations of Liquid Acid Reduction Anti-Epigastrlgics/Sucralfate Type Compound

	mg/5 ml
Cimetidine or **Ranitidine** or **Nizatidine** or **Famotidine** or Omerprazole	20-300
Calcium Carbonate	400-500
Sucralfate [a poly[phosphoryl/ sulfon]-ated carbohydrate] or Sucrose Octasulfate	100-500
.+-.Simethecone	40-80
Methyl Paraben USP	5-10
Propyl Paraben USP	5-10
Sodium Saccharin	3.0- 5.0
Sorbitol USP	200-350
Flavor	q.s.
Water	5000

L17 ANSWER 15 OF 33 USPATFULL

ACCESSION NUMBER: 93:20560 USPATFULL

TITLE: Enteric film and preparatoin thereof

INVENTOR(S): Itoh, Shunichi, Suita, Japan
Koyama, Hiroyoshi, Mishima, Japan
Kashihara, Toshio, Suita, Japan
Hirai, Shin-ichiro, Kyoto, Japan

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	DATE

PATENT INFORMATION:	US 5194464	19930316
APPLICATION INFO.:	US 1990-497655	19900323 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-412439, filed on 26 Sep 1989, now abandoned	
	NUMBER	DATE
PRIORITY INFORMATION:	JP 1988-243542	19880927
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Kight, III, John	
ASSISTANT EXAMINER:	Hampton-Hightower, P.	
LEGAL REPRESENTATIVE:	Wegner, Cantor, Mueller & Player	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	609	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An enteric film is produced by spraying on a material a mixed solution of (a) hydroxypropylmethylcellulose phthalate exhibiting a viscosity of about 136 to 204 centistokes as 10% methanol/dichloromethane (1:1 by weight) solution at 20.degree. C., (b) polyethylene glycol presenting solid state at ambient temperature and (c) shellac, wherein respective ratios of (b) and (c) to (a) are 0.1 to 20 weight percent and 5 to 40 weight percent; and then drying the solution.

The enteric film excels in film strength and acid resistance, and can be employed in pharmaceutical preparations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . drugs of benzimidazole series having anti-ulcer activity being exemplified by 2-[(3-methyl-4-(2,2,2-trifluoroethoxy)2-pyridyl)methylsulfinyl]benzimidazole, (hereinafter referred to sometimes as "Compound A") and 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)-methylsulfinyl]benzimidazole, **cimetidine**, **ranitidine**, pancreatin, bisacodyl and 5-aminosalicylic acid; antibiotics and chemotherapeutic agents, such as cephalexin, cephaclor, cefradine, amoxixillin, pivampicillin, bacampicillin, dicloxacillin, erythromycin, erythromycin. . . active ingredient. As the additive, there may be mentioned, for example, excipients (e.g. lactose, corn starch, sucrose, talc, crystalline cellulose, **mannitol**, light anhydrous silicic acid, magnesium carbonate, **calcium carbonate**, L-cysteine, etc.), binders (e.g. pregelatinized starch, methylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, pullulan, dextrin, gum arabic, low substituted hydroxypropylcellulose (hereinafter referred. . .

L17 ANSWER 16 OF 33 USPATFULL

ACCESSION NUMBER:	93:16465 USPATFULL
TITLE:	Oral or detergent composition comprising a nonionic surface active agent
INVENTOR(S):	Sekiguchi, Shizuo, Funabashi, Japan Yasumasu, Tomoko, Funabashi, Japan Miyake, Hiroshi, Narashino, Japan Endo, Yoshihisa, Sakura, Japan
PATENT ASSIGNEE(S):	Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5190747	19930302
APPLICATION INFO.:	US 1992-827463	19920129 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1990-608738, filed on 5 Nov 1990, now patented, Pat. No. US 5109127	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1989-288154	19891106

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Ronald W.
ASSISTANT EXAMINER: Leary, Louise
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1719
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral detergent composition comprising a nonionic surface active agent comprising a fatty acid ester of a hexose sugar or an alkyl glycoside thereof, wherein the content of monoester is from 93 to 99.0% by weight, the content of diester is from 0.1 to 7% by weight and the content of tri- and higher polyesters is from 0 to 1% by weight in the fatty acid ester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . liquid dentifrice, mouthwash and artificial teeth detergent. For the dentifrice, there can be used abrasives such as calcium secondary phosphate, **calcium carbonate**, calcium pyrophosphate, insoluble sodium metaphosphate, aluminum hydroxide, silica and silicate (blending amount: 10 to 95% by weight based on the entire composition), humectants such as glycerol, **sorbitol**, propylene glycol and polyethylene glycol (blending amount: 10 to 70% by weight based on the entire composition), binders such as. . . menthol, carvone and anethol. If required, fluorides such as sodium monofluorophosphate, sodium fluoride and tin fluoride, anti-inflammatory agents such as **tranexamic acid**, .epsilon.-aminocaproic acid and allantoinate, phosphoric acid compound such as sodium polyphosphate and like other phermaceutical agents can be used.

DETD

Blending Example 1 (Toothpaste)

Glucose octanoate	1.5%
Calcium hydrogen phosphate	15
Silica	15
Sorbitol	30
Sodium carboxymethyl cellulose	1
Flavor and coloring agent	appropriate amount
Water	balance
Total	100.0%

Blending Example 2 (Kitchen detergent)

Glucose octanoate	10%
Alcohol ethoxylate sulfate (Na. . . and dye	appropriate amount
Water	balance
Total	100.0%

Glucose ester No. 1
Glucose monooctanoate 90%
Glucose monodacanoate 10%
Blending Example 4 (Toothpaste)

Calcium secondary phosphate dihydrate	45.0%
Glycerol	5.0
Sorbitol	15.0
Sodium carboxymethyl cellulose	1.0
Glucose ester No. 2	1.5
Flavor and sweetener	appropriate amount
Water	balance
Total	100.0%

Glucose ester No. 2
Glucose monooctanoate 80%
Glucose monodecanoate. . . 5.0

Perfume	appropriate amount
Water	balance
Total	100.0%

Glucose ester No. 4
Glucose monooctanoate 85%
Glucose monodecanoate 15%
Blending Example 7 (Toothpaste)

Aluminum hydroxide	40.0%
Silicic anhydride	2.0
Propylene glycol	3.0
Sorbitol	26.0
Sodium alginate	1.0
Sodium saccharinate	0.2
Glucose-5-monolaurate	0.7
Sodium lauryl sulfate	0.7
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 8 (Toothpaste)

Calcium secondary phosphate	45.0%
Silicic anhydride	3.0
Sodium carboxymethyl cellulose	1.0
Carrageenan	0.2
Propylene glycol	3.0
Sorbitol	26.0
Sodium saccharinate	0.2
Sodium monofluorophosphate	0.76
Glucose-6-monolaurate	1.0
Sodium lauryl sulfate	0.5
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 9 (Toothpaste)

Calcium secondary phosphate	45.0%
Silicic anhydride	3.0
Aluminum oxide	1.0
Propylene glycol	3.0

Sorbitol 25.0
Sodium carboxymethyl cellulose 0.8
Carrageenan 0.3
Sodium saccharinate 0.2
Glucose-6-monocaprate 1.0
Sodium lauryl sulfate 0.5
Arantoin chlorohydroxy aluminum 0.1
Flavor 1.0
Preservative trace
Purified water balance
Total 100.0%

Blending Example 10 (Toothpaste)
Zirconosilicate 15.0%
Silicic anhydride 2.0
Polyethylene glycol 400 3.0
Sorbitol 60.0
Sodium carboxymethyl cellulose 1.4
Sodium saccharinate 0.2
Glucose-6-monocaprate 1.5
Sodium lauryl sulfate 0.5
.beta.-glycyrrhetinic acid 0.01
Tocopherol acetate 0.1
Flavor 1.0
Coloring agent trace
Purified water balance
Total 100.0%

Blending Example 11 (Toothpaste)
Aluminosilicate 20.0%
Glycerol 15.0
Sorbitol 40.0
Polyethylene glycol 400 4.0
Sodium carboxymethyl cellulose 1.2
Sodium saccharinate 0.2
Glucose-6-monocaprate 1.0
Sodium lauryl sulfate 0.5
Flavor 1.0
Coloring agent trace
Purified water balance
Total 100.0%

Blending Example 12 (Toothpaste)
Calcium carbonate (heavy) 30.0%
Calcium carbonate (light) 15.0
Propylene glycol 3.0
Sorbitol 30.0
Sodium carboxymethyl cellulose 1.0
Sodium saccharinate 0.1
Tranexamic acid 0.1
Glucose-6-monocaprate 1.5
Sodium myristyl sulfate 0.5

Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 13 (Toothpower)

Calcium secondary phosphate	35.0%
Calcium carbonate	40.0
Glycerol	10.0
Sodium carboxymethyl cellulose	0.3
Sodium saccharinate	0.2
Glucose-6-monolaurate	1.0
Sodium lauryl sulfate	0.5
Flavor	1.5
Purified water	balance
Total	100.0%

Blending Example 14 (Mouthwash)

Ethanol	10.0%
Glycerol	10.0
Sorbitol	5.0
Citric acid	0.1
Sodium citrate	0.4
Sodium saccharinate	0.05
Glucose-6-monocaprylate	1.0
Sodium lauryl sulfate	0.5
Flavor	1.0
Purified water	balance
Total	100.0%

Blending Example 15 (Toothpaste)

Aluminum hydroxide	40.0%
Silicic anhydride	2.0
Propylene glycol	3.0
Sorbitol	15.0
Glycerol	15.0
Sodium alginate	1.0
Sodium saccharinate	0.2
Glucose-6-monolaurate	1.5
Sodium N-lauroyl glutamate	0.5
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 16 (Toothpaste)

Aluminum silicate	20.0%
Glycerol	15.0
Sorbitol	40.0
Polyethylene glycol 400	4.0
Sodium carboxymethyl cellulose	1.2
Sodium saccharinate	0.2
Glucose-6-monocaprate	1.0
Sodium N-lauroyl sarcosinate	0.5
Flavor	1.0
Coloring agent	slight amount
Purified water	balance

Total	100.0%

Blending Example 17 (Toothpaste)

Calcium carbonate (heavy)	30.0%
Calcium carbonate (light)	15.0
Propylene glycol	3.0
Sorbitol	30.0
Sodium carboxymethyl cellulose	1.0
Sodium saccharinate	0.1
Tranexamic acid	0.1
Glucose-6-monocaprylate	1.5
Sodium N-myristoylmethyl- -alanine	0.5
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 18 (Toothpaste)

Calcium secondary phosphate	45.0%
Silicic anhydride	3.0
Aluminum oxide	1.0
Propylene glycol	3.0
Sorbitol	25.0
Sodium carboxymethyl cellulose	0.8
Carrageenan	0.3
Sodium saccharinate	0.2
Glucose-6-monocaprate	1.0
Sodium N-lauroyl sarcosinate	0.5
Arantoin chlorohydroxy aluminum	0.1
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 19 (Toothpaste)

Zirconosilicate	15.0%
Silicic anhydride	2.0
Polyethylene glycol 400	3.0
Sorbitol	60.0
Sodium carboxymethyl cellulose	1.4
Sodium saccharinate	0.2
Glucose-6-monocaprylate	1.5
Sodium N-lauroylmethyl-.beta.-alanine	0.5
.beta.-glycyrretic acid	0.01
Tocopherol acetic acid	0.1
Flavor	1.0
Coloring agent	trace
Purified water	balance
Total	100.0%

Blending Example 20 (Toothpowder)

Calcium secondary phosphate	35.0%
Calcium carbonate	40.0
Glycerol	10.0
Sodium carboxymethyl cellulose	0.3
Sodium saccharine	0.2
Glucose-6-monolaurate	1.0
Sodium N-myristoyl sarcosinate	0.5
Flavor	1.5
Purified water	balance
Total	100.0%

Blending Example 21 (Mouthwash)

Ethanol	10.0%
Glycerol	10.0
Sorbitol	5.0
Citric acid	0.1
Sodium citrate	0.4
Sodium saccharinate	0.05
Glucose-6-monocaprylate	1.0
Sodium N-lauryol sarcosinate	0.5
Flavor	1.0
Purified water	balance
Total	100.0%

Blending Example 22 (Toothpaste)

Aluminum hydroxide	45.0%
Sodium carboxymethyl cellulose	0.8
Carrageenan	0.2
Sorbitol	26.0
Propylene glycol	3.0
Sodium saccharinate	0.2
Sodium N-myristoyl taurine	1.5
Glucose-6-monolaurate	3.0
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 23 (Mouthwash)

Ethanol	10.0%
Glycerol	15.0
Citric acid. . .	

L17 ANSWER 17 OF 33 USPATFULL

ACCESSION NUMBER:	93:14374 USPATFULL		
TITLE:	Pharmaceutical compositions of cimetidine		
INVENTOR(S):	Pearmain, Kevin E., Hitchin, England		
PATENT ASSIGNEE(S):	Smith Kline & French Laboratories Ltd., Hertfordshire, United Kingdom (non-U.S. corporation)		
	NUMBER	DATE	
PATENT INFORMATION:	US 5188839	19930223	
	WO 8808703	19881117	
APPLICATION INFO.:	US 1989-295190	19890104	(7)

WO 1988-GB349 19880504
19890104 PCT 371 date
19890104 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1987-10965	19870508
	GB 1987-10966	19870508

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Dinner, Dara L.; Suter, Stuart R.; Lentz, Edward T.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 331
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a pharmaceutical granule comprising cimetidine and 2-20% (w/w) relative to the cimetidine of a co-polymer of dimethylaminoethylmethacrylate and neutral methacrylic acid esters. Compositions of this invention have good palatability and dissolution characteristics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD

	mg/tablet
Active constituents	
Cimetidine	200.0
Alginic acid	500.0
Other constituents	
Sodium Bicarbonate	170
Eudragit E100	20
Sorbitol	680
Pregelatinised Starch	30
Croscarmellose Sodium Type A	60
Lactose	330
Aspartame	5
Sodium Saccharin	5
Magnesium Stearate	35*
Flavourings	50

*A range of 15 to 35. . .

L17 ANSWER 18 OF 33 USPATFULL
ACCESSION NUMBER: 93:5237 USPATFULL
TITLE: Composition for enhancing oral hygiene, containing bamboo-salt
INVENTOR(S): Ha, Jae M., Pongmyung-dong, Korea, Republic of
Jeong, Kwang L., Pongmyung-dong, Korea, Republic of
Suh, Sung S., Pongmyung-dong, Korea, Republic of
PATENT ASSIGNEE(S): Lucky, Ltd., Seoul, Korea, Republic of (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5180575	19930119	
APPLICATION INFO.:	US 1991-813934	19911227	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	KR 1990-22099	19901228

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to an oral hygiene composition which comprises a 0.1 to 30% by weight of a bamboo-salt alone based on the total weight of the composition or a mixture of bamboo-salt and sodium chloride said mixture being in a mixed ratio of 1:5 to 1:15.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . a toothpaste composition includes conventional tooth paste components, for example, polishing agents such as dicalcium phosphate, silicon dioxide aluminum hydroxide, **calcium carbonate** and the like; humectants such as **sorbitol**, glycerin, polyethylene glycol and the like; foaming agents such as sodium alkylsulphate, polyoxyethylene-polyoxypropylene condensation polymer and the like; sweetening agents. . . and the like; preservatives such as methyl paraoxy benzoic acid and the like; therapeutic agents such as sodium fluoride, chlorhexidine, **tranexamic acid**, allantoin and the like; and the binders. The toothpaste composition may be prepared by adding 0.1-30% by weight of a. . .

L17 ANSWER 19 OF 33 USPATFULL
ACCESSION NUMBER: 92:106654 USPATFULL
TITLE: Oral composition
INVENTOR(S): Tanaka, Kumiko, Yokohama, Japan
Fujii, Seishiro, Yokohama, Japan
PATENT ASSIGNEE(S): Shiseido Company Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5174989	19921229
APPLICATION INFO.:	US 1990-572326	19900821 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1988-250466, filed on 28 Sep 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1987-296374	19871125

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Sprung Horn Kramer & Woods
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 556
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An oral composition comprising (i) at least one fluoride compound and (ii) at least one 5- or 6-membered, substituted heterocyclic compound which contains 1 to 3 nitrogen atoms as ring hetero atoms, which may contain an oxygen or sulfur atom as a ring hetero atom, and which may be condensed with one or two 6-membered carbocyclic or heterocyclic rings,

or a salt thereof. This oral composition is very effective for preventing carries of the teeth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . additives are a polishing agent such as calcium phosphate (dibasic) dihydrate or anhydrate thereof, calcium phosphate (monobasic), calcium phosphate (tribasic), **calcium carbonate**, calcium pyrophosphate, titanium oxide, aluminum hydroxide, aluminum oxide, silica polishing agent (e.g., amorphous silica, crystalline silica, complex of alkali metal. . . carbonate, magnesium sulfate, calcium sulfate, methyl polymethacrylate, bentonite, zirconium silicate, hydroxyapatite or synthetic polymer; a wetting agent such as glycerol, **sorbitol**, propylene glycol, polyethylene glycol, ethylene glycol, 1,3-butylene glycol, **xylitol**, maltitol, or lactitol; a thickening agent such as carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose, sodium carboxymethylhydroxyethyl cellulose, sodium alginate, carrageenan,. . . protease, lytic enzyme, mutase, mutastein, sorbic acid, alexin, .beta.-glycyrrhetinic acid, hinokitiol, dihydrocholesterol, epidihydrocholesterol, alkyl glycine, alkyldiaminoethylglycine salt, allantoin, .epsilon.-aminocaproic acid, **tranexamic acid**, azulene, other vitamins, water soluble salt of phosphoric acid (mono- or dibasic), quaternary ammonium compound (e.g., cetylpyridinium chloride), sodium chloride,. . .

L17 ANSWER 20 OF 33 USPATFULL
ACCESSION NUMBER: 92:34283 USPATFULL
TITLE: Nonionic surface active agent
INVENTOR(S): Sekiguchi, Shizuo, Funabashi, Japan
Yasumasu, Tomoko, Funabashi, Japan
Miyake, Hiroshi, Narashino, Japan
Endo, Yoshihisa, Sakura, Japan
PATENT ASSIGNEE(S): Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5109127	19920428	
APPLICATION INFO.:	US 1990-608738	19901105	(7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1989-288154	19891106

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Ronald W.
ASSISTANT EXAMINER: Leary, Louise
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 1639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A nonionic surface active agent comprising a fatty acid ester of a hexose sugar or an alkyl glycoside thereof, wherein the content of monoester is from 93 to 99.9% by weight, the content of diester is from 0.1 to 7% by weight and the content of tri- and higher polyesters is from 0 to 1% by weight in the fatty acid ester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . liquid dentifrice, mouthwash and artificial teeth detergent. For the dentifrice, there can be used abrasives such as calcium

secondary phosphate, **calcium carbonate**, calcium pyrophosphate, insoluble sodium metaphosphate, aluminum hydroxide, silica and silicate (blending amount: 10 to 95% by weight based on the entire composition), humectants such as glycerol, **sorbitol**, propylene glycol and polyethylene glycol (blending amount: 10 to 70% by weight based on the entire composition), binders such as. . . menthol, carvone and anethol. If required, fluorides such as sodium monofluorophosphate, sodium fluoride and tin fluoride, anti-inflammatory agents such as **tranexamic acid**, .epsilon.-aminocaproic acid and allantoinate, phosphoric acid compound such as sodium polyphosphate and like other phermaceutical agents can be used.

DETD

Blending Example 1 (Toothpaste)

Glucose octanoate	1.5%
Calcium hydrogen phosphate	15
Silica	15
Sorbitol	30
Sodium carboxymethyl cellulose	1
Flavor and coloring agent	appropriate amount
Water	balance
Total	100.0%

Blending Example 2 (Kitchen detergent)

Glucose octanoate	10%
Alcohol ethoxylate sulfate (Na. . . and dye	appropriate amount
Water	balance
Total	100.0%

Glucose ester No. 1

Glucose monooctanoate	90%
Glucose monodacanoate	10%

Blending Example 4 (Toothpaste)

Calcium secondary phosphate dihydrate	45.0%
Glycerol	5.0
Sorbitol	15.0
Sodium carboxymethyl cellulose	1.0
Glucose ester No. 2	1.5
Flavor and sweetener	appropriate amount
Water	balance
Total	100.0%

Glucose ester No. 2

Glucose monooctanoate	80%
Glucose monodecanoate. . .	5.0
Perfume	appropriate amount
Water	balance
Total	100.0%

Glucose ester No. 4

Glucose monooctanoate	85%
Glucose monodecanoate	15%

Blending Example 7 (Toothpaste)

Aluminum hydroxide	40.0%
Silicic anhydride	2.0

Propylene glycol	3.0
Sorbitol	26.0
Sodium alginate	1.0
Sodium saccharinate	0.2
Glucose-5-monolaurate	0.7
Sodium lauryl sulfate	0.7
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 8 (Toothpaste)

Calcium secondary phosphate	45.0%
Silicic anhydride	3.0
Sodium carboxymethyl cellulose	1.0
Carrageenan	0.2
Propylene glycol	3.0
Sorbitol	26.0
Sodium saccharinate	0.2
Sodium monofluorophosphate	0.76
Glucose-6-monolaurate	1.0
Sodium lauryl sulfate	0.5
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 9 (Toothpaste)

Calcium secondary phosphate	45.0%
Silicic anhydride	3.0
Aluminum oxide	1.0
Propylene glycol	3.0
Sorbitol	25.0
Sodium carboxymethyl cellulose	0.8
Carrageenan	0.3
Sodium saccharinate	0.2
Glucose-6-monocaprate	1.0
Sodium lauryl sulfate	0.5
Arantoin chlorohydroxy aluminum	0.1
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 10 (Toothpaste)

Zirconosilicate	15.0%
Silicic anhydride	2.0
Polyethylene glycol 400	3.0
Sorbitol	60.0
Sodium carboxymethyl cellulose	1.4
Sodium saccharinate	0.2
Glucose-6-monocaprate	1.5
Sodium lauryl sulfate	0.5
.beta.-glycyrrhetinic acid	0.01
Tocopherol acetate	0.1

Flavor	1.0
Coloring agent	trace
Purified water	balance
Total	100.0%

Blending Example 11 (Toothpaste)

Aluminosilicate	20.0%
Glycerol	15.0
Sorbitol	40.0
Polyethylene glycol 400	4.0
Sodium carboxymethyl cellulose	1.2
Sodium saccharinate	0.2
Glucose-6-monocaprate	1.0
Sodium lauryl sulfate	0.5
Flavor	1.0
Coloring agent	trace
Purified water	balance
Total	100.0%

Blending Example 12 (Toothpaste)

Calcium carbonate (heavy)	30.0%
Calcium carbonate (light)	15.0
Propylene glycol	3.0
Sorbitol	30.0
Sodium carboxymethyl cellulose	1.0
Sodium saccharinate	0.1
Tranexamic acid	0.1
Glucose-6-monocaprate	1.5
Sodium myristyl sulfate	0.5
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 13 (Toothpower)

Calcium secondary phosphate	35.0%
Calcium carbonate	40.0
Glycerol	10.0
Sodium carboxymethyl cellulose	0.3
Sodium saccharinate	0.2
Glucose-6-monolaurate	1.0
Sodium lauryl sulfate	0.5
Flavor	1.5
Purified water	balance
Total	100.0%

Blending Example 14 (Mouthwash)

Ethanol	10.0%
Glycerol	10.0
Sorbitol	5.0
Citric acid	0.1
Sodium citrate	0.4
Sodium saccharinate	0.05
Glucose-6-monocaprylate	1.0
Sodium lauryl sulfate	0.5
Flavor	1.0
Purified water	balance
Total	100.0%

Blending Example 15 (Toothpaste)

Aluminum hydroxide	40.0%
Silicic anhydride	2.0
Propylene glycol	3.0
Sorbitol	15.0
Glycerol	15.0
Sodium alginate	1.0
Sodium saccharinate	0.2
Glucose-6-monolaurate	1.5
Sodium N-lauroyl glutamate	0.5
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 16 (Toothpaste)

Aluminum silicate	20.0%
Glycerol	15.0
Sorbitol	40.0
Polyethylene glycol 400	4.0
Sodium carboxymethyl cellulose	1.2
Sodium saccharinate	0.2
Glucose-6-monocaprate	1.0
Sodium N-lauroyl sarcosinate	0.5
Flavor	1.0
Coloring agent	slight amount
Purified water	balance
Total	100.0%

Blending Example 17 (Toothpaste)

Calcium carbonate (heavy)	30.0%
Calcium carbonate (light)	15.0
Propylene glycol	3.0
Sorbitol	30.0
Sodium carboxymethyl cellulose	1.0
Sodium saccharinate	0.1
Tranexamic acid	0.1
Glucose-6-monocaprylate	1.5
Sodium N-myristoylmethyl- -alanine	0.5
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 18 (Toothpaste)

Calcium secondary phosphate	45.0%
Silicic anhydride	3.0
Aluminum oxide	1.0
Propylene glycol	3.0
Sorbitol	25.0
Sodium carboxymethyl cellulose	0.8
Carrageenan	0.3
Sodium saccharinate	0.2
Glucose-6-monocaprate	1.0

Sodium N-lauroyl sarcosinate	0.5
Arantoin chlorohydroxy aluminum	0.1
Flavor	1.0
Preservative	trace
Purified water	balance
Total	100.0%

Blending Example 19 (Toothpaste)

Zirconosilicate	15.0%
Silicic anhydride	2.0
Polyethylene glycol 400	3.0
Sorbitol	60.0
Sodium carboxymethyl cellulose	1.4
Sodium saccharinate	0.2
Glucose-6-monocaprylate	1.5
Sodium N-lauroylmethyl-.beta.-alanine	0.5
.beta.-glycyrretic acid	0.01
Tocopherol acetic acid	0.1
Flavor	1.0
Coloring agent	trace
Purified water	balance
Total	100.0%

Blending Example 20 (Toothpowder)

Calcium secondary phosphate	35.0%
Calcium carbonate	40.0
Glycerol	10.0
Sodium carboxymethyl cellulose	0.3
Sodium saccharine	0.2
Glucose-6-monolaurate	1.0
Sodium N-myristoyl sarcosinate	0.5
Flavor	1.5
Purified water	balance
Total	100.0%

Blending Example 21 (Mouthwash)

Ethanol	10.0%
Glycerol	10.0
Sorbitol	5.0
Citric acid	0.1
Sodium citrate	0.4
Sodium saccharinate	0.05
Glucose-6-monocaprylate	1.0
Sodium N-lauryol sarcosinate	0.5
Flavor	1.0
Purified water	balance
Total	100.0%

Blending Example 22 (Toothpaste)

Aluminum hydroxide	45.0%
Sodium carboxymethyl cellulose	0.8
Carrageenan	0.2
Sorbitol	26.0
Propylene glycol	3.0
Sodium saccharinate	0.2

Sodium N-myristoyl taurine
1.5
Glucose-6-monolaurate 3.0
Flavor 1.0
Preservative trace
Purified water balance
Total 100.0%
Blending Example 23 (Mouthwash)
Ethanol 10.0%
Glycerol 15.0
Citric acid. . .

L17 ANSWER 21 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1992-365958 [44] WPIDS
DOC. NO. CPI: C1992-162437
TITLE: Chewable antacid tablets - made by direct compression of dry-mixed pre-granulated antacid and granulated mannitol.
DERWENT CLASS: B07
INVENTOR(S): COURT, P R; RUSSELL, C M; UPSON, J G
PATENT ASSIGNEE(S): (PROC) PROCTER & GAMBLE CO
COUNTRY COUNT: 38
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9217161	A1	19921015	(199244)*	EN	13
RW: AT BE CH DE DK ES FR GB GR IT LU MC NL OA SE					
W: AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE					
AU 9216746	A	19921102	(199305)		
EP 578732	A1	19940119	(199403)	EN	
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
CZ 9302258	A3	19940413	(199422)		
JP 06505498	W	19940623	(199429)		6
HU 65753	T	19940728	(199431)		
SK 9301211	A3	19940706	(199432)		
BR 9205824	A	19940628	(199433)		
AU 665944	B	19960125	(199611)		
EP 578732	B1	19960619	(199629)	EN	7
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
DE 69211688	E	19960725	(199635)		
CA 2106216	C	19970610	(199735)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9217161	A1	WO 1992-US1982	19920313
AU 9216746	A	AU 1992-16746	19920313
		WO 1992-US1982	19920313
EP 578732	A1	EP 1992-909364	19920313
		WO 1992-US1982	19920313
CZ 9302258	A3	CZ 1993-2258	19920313
JP 06505498	W	JP 1992-508912	19920313
		WO 1992-US1982	19920313
HU 65753	T	WO 1992-US1982	19920313
		HU 1993-2971	19920313
SK 9301211	A3	WO 1992-US1982	19920313
		SK 1993-1211	19931101

BR 9205824	A	BR 1992-5824	19920313
		WO 1992-US1982	19920313
AU 665944	B	AU 1992-16746	19920313
EP 578732	B1	EP 1992-909364	19920313
		WO 1992-US1982	19920313
DE 69211688	E	DE 1992-611688	19920313
		EP 1992-909364	19920313
		WO 1992-US1982	19920313
CA 2106216	C	CA 1992-2106216	19920313

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9216746	A	Based on	WO 9217161
EP 578732	A1	Based on	WO 9217161
JP 06505498	W	Based on	WO 9217161
HU 65753	T	Based on	WO 9217161
BR 9205824	A	Based on	WO 9217161
AU 665944	B	Previous Publ.	AU 9216746
		Based on	WO 9217161
EP 578732	B1	Based on	WO 9217161
DE 69211688	E	Based on	EP 578732
		Based on	WO 9217161

PRIORITY APPLN. INFO: US 1991-680498 19910404; WO 1992-US1982 19920313

AN 1992-365958 [44] WPIDS

AB WO 9217161 A UPAB: 19931116
Chewable **antacid** tablets are produced by dry mixing a pregranulated **antacid** (I) with granulated **mannitol** (II) and directly compressing the mixt. (N.B., **antacids** are defined as comprising not only conventional **antacid** bases and Bi cpds. but also histamine H2 antagonists such as **cimetidine** and anti-ulcer drugs such as sucralfate).

Pref. the tablets comprise 35-50% (I), 40-60% (II) and 1-25% excipients from wetting agents, lubricants, tabletting aids, stabilisers, antioxidants, sweeteners and cooling agents. (I) comprises 80-95% CaCO3, 0.1-5% gelatin and 1-20% glucose. The cooling agent is esp. 3-(1-menthyloxy)-1,2-propanediol (MPD), present in an amt. of 0.01-0.5%
Dwg.0/0

ABEQ EP 578732 B UPAB: 19960724
A compressed compositions in unit dosage form suitable for ingestion by chewing comprising: (a) pre-granulated antacid agent which has been granulated with gelatin and at least one simple sugar which is a monosaccharide or disaccharide which is safe and effective for ingestion by a human; and (b) granulated mannitol.
Dwg.0/0

AB WO 9217161 UPAB: 19931116
Chewable **antacid** tablets are produced by dry mixing a pregranulated **antacid** (I) with granulated **mannitol** (II) and directly compressing the mixt. (N.B., **antacids** are defined as comprising not only conventional **antacid** bases and Bi cpds. but also histamine H2 antagonists such as **cimetidine** and anti-ulcer drugs such as sucralfate).

Pref. the tablets comprise 35-50% (I), 40-60% (II) and 1-25% excipients from wetting agents,. . .

L17 ANSWER 22 OF 33 USPATFULL
ACCESSION NUMBER: 91:100154 USPATFULL

TITLE: Shape retentive oral composition for dental applications
INVENTOR(S): Yoshie, Makoto, Yokohama, Japan
Seto, Shinichi, Tokyo, Japan
Takahashi, Fumito, Sagamihara, Japan
PATENT ASSIGNEE(S): Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5071638	19911210
APPLICATION INFO.:	US 1987-136385	19871222 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1986-308522	19861226

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Griffin, Ronald W.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 607
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An oral composition containing (i) fumed silica and polyethylene glycol having an average molecular weight of 2000 to 6000.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD

Ingredient	wt. %
Calcium carbonate	25
Sorbitol liquid	40
Polyethylene glycol 2000	3.0
Sodium polyacrylate	1.5
Tranexamic acid	0.05
Fumed silica (Cab-O-Sil M-7)	2.0
Saccharin sodium	0.2
Methyl parahydroxybenzoate	0.2
Flavor	1.0
Sodium laurylsulfate	1.3
Sodium lauroylsarcosinate	0.3
Purified water	Balance
Total	100.0 wt. %
Viscosity	700. . .

L17 ANSWER 23 OF 33 USPATFULL
ACCESSION NUMBER: 91:60625 USPATFULL
TITLE: Dentifrice composition
INVENTOR(S): Mori, Shigeki, Takatsuki, Japan
Makino, Chiho, Takatsuki, Japan
PATENT ASSIGNEE(S): Sunstar Kabushiki Kaisha, Osaka, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5035881	19910730

APPLICATION INFO.: US 1990-509344 19900416 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1989-104151	19890424

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Wegner, Cantor, Mueller & Player
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A dentifrice composition containing a bactericide selected from the group consisting of biguanido bactericides and N-alkyldiaminoethylglycine, a polyoxyethylenepolyoxypropylene block copolymer surfactant and a N-higher acylamino acid or its salt is disclosed. The dentifrice composition maintains bactericidal activities of the bactericide added.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . the present invention is not damaged, appropriate ingredients, for example, polishing agents such as calcium secondary phosphate anhydride or dihydrate, **calcium carbonate**, calcium pyrophosphate, insoluble sodium metaphosphate, aluminum hydroxide, aluminum oxide, a resin and the like; humectants such as polyethylene glycol, **sorbitol**, glycerin, propylene glycol and the like; essential oils such as peppermint, spearmint and the like; flavors such as 1-menthol, carvone,. . . aldehyde, thaumatin and the like; pharmacologically active ingredients such as sodium monofluorophosphate, sodium fluoride, dextranase, mutanase, hinokitiol, allantoin, ,-aminocaproic acid, **tranexamic acid**, azulene, vitamin E derivatives, sodium chloride and the like can be added at need.

L17 ANSWER 24 OF 33 USPATFULL
ACCESSION NUMBER: 91:40351 USPATFULL
TITLE: Paste-like dentifrice composition
INVENTOR(S): Mitsutake, Hiromi, Yokohama, Japan
Saitoh, Hideomi, Sagamihara, Japan
Nagata, Koichiro, Yokkaichi, Japan
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5017364	19910521
APPLICATION INFO.:	US 1989-422460	19891017 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1988-264464	19881020

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
LINE COUNT: 358
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Herein is disclosed a paste-like dentifrice composition containing, as

the foaming agent, from 0.1 to 5.0% by weight of highly pure N-long-chain acylglutamate which contains not more than 1.0% by weight of higher fatty acid(s), either in the free form or in the salt form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . that they may act as effective components of the composition: an abrasive such as calcium secondary phosphate or its dihydrate, **calcium carbonate**, calcium pyrophosphate, insoluble sodium metaphosphate, silicic acid anhydride, silicic acid hydrate, alumino-silicate, alumina, or aluminum hydroxide; a viscosity agent such as glycerin, **sorbitol**, propylene glycol, or polyethylene glycol; a caking agent such as carboxymethyl cellulose, carrageenan, sodium alginate, bee gum, hydroxethyl cellulose, or. . . phosphate builder such as sodium phosphate; an enzyme such as dextranase, or amylase; an anti-inflammatory agent such as .epsilon.-aminocaproic acid, **tranexamic acid**, or allantoinate; and a gingival astringent such as sodium chloride.

L17 ANSWER 25 OF 33 USPATFULL

ACCESSION NUMBER:	90:25560 USPATFULL	
TITLE:	Oral composition	
INVENTOR(S):	Miyake, Mikio, Kanagawa, Japan Takahashi, Akinori, Kanagawa, Japan	
PATENT ASSIGNEE(S):	Lion Corporation, Tokyo, Japan (non-U.S. corporation)	
	NUMBER	DATE
PATENT INFORMATION:	US 4913895	19900403
APPLICATION INFO.:	US 1987-76211	19870722 (7)
	NUMBER	DATE
PRIORITY INFORMATION:	JP 1986-174026	19860724
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Rose, Shep K.	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	412	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral composition comprising (i) at least one phosphate selected from the group consisting of linear polyphosphates of the formula (I):

M.sub.n+2 P.sub.n O.sub.3n+1 (I)

wherein M represents Na or K and N .gtoreq.2, and cyclic polyphosphates of the formula (II):

(M'PO.sub.3).sub.m (II)

wherein M' represents Na or K and m.gtoreq.3 and (iii) l-menthol, anethol, or the mixture thereof in an aqueous medium. This oral composition has an excellent antibacterial effect and prevents the development of calculus and periodontal diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM For example, abrasives such as calcium phosphate (dibasic), **calcium carbonate**, calcium pyrophosphate, insoluble

sodium metaphosphate, aluminum oxide, aluminum hydroxide, silica, silicates and resins; binders such as sodium carboxymethyl cellulose, hydroxyethyl cellulose, alginate, carageenan, gum arabic, polyvinyl alcohol, and colloidal silica; humectants such as polyethylene glycol, **sorbitol**, glycerol, and propylene glycol; surfactants such as sodium lauryl sulfate, sodium dodecylbenzene sulfonate, sodium hydrogenated cococut fatty acid monoglyceride monosulfate,. . . components such as chlorohexidines, dextranase, mutanase, sorbin acid, alexidine, hinokitiol, cetyl pyridinium chloride, alkylglycines, alkyldiaminoethyl glycine salts, allantoin, .epsilon.-aminocaproic acid,

tranexamic acid, azulene, vitamin E, water-soluble monobasic or dibasic phosphates, quaternary ammonium compounds and sodium chloride may be formulated into the present. . .

L17 ANSWER 26 OF 33 USPATFULL

ACCESSION NUMBER:	89:76252 USPATFULL	
TITLE:	Oral composition containing a polyglycerol fatty acid monoester and an N-acylamino acid or a salt thereof	
INVENTOR(S):	Saso, Kazuo, Hiratsuka, Japan	
PATENT ASSIGNEE(S):	Lion Corporation, Tokyo, Japan (non-U.S. corporation)	
	NUMBER	DATE
PATENT INFORMATION:	US 4865839	19890912
APPLICATION INFO.:	US 1987-92189	19870902 (7)
	NUMBER	DATE
PRIORITY INFORMATION:	JP 1986-206410	19860902
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Moskowitz, Margaret	
ASSISTANT EXAMINER:	Moezie, F. T.	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	433	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral composition containing, as a surfactant, polyglycerol fatty acid monoester having a polymerization degree of glycerol of 6 or more and 10 to 20 carbon atoms in the fatty acid moiety. An N-acylamino acid or a salt thereof may be contained in this oral composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . ingredients, depending upon the types of the oral compositions.

For example, dentifrices may optionally contain abrasives such as dicalcium phosphate, **calcium carbonate**, calcium pyrophosphate, insoluble sodium methaphosphate, and silicic anhydride; thickening agents such as glycerol, **sorbitol**, propylene glycol, and poyethylene glycol; binders such as carboxymethyl cellulose, carrageenan, sodium alginate, bees gum, hydroxyethyl cellulose, and polyvinyl alcohol;. . . and chlorohexidine salts; phosphate compounds such as sodium phosphate; enzymes such as dextranase and amylase; anti-inflammatories such as E-aminocaproic acid, **tranexamic acid**, and allantoinate; and other effective components also may

be optionally formulated. Also, in the case of oral clearers such as.

.

.

DETD

Example 1: Tooth paste

Formulation	%
Aluminosilicate	20.0
Glycerol	15.0
Sorbitol liquid	40.0
Polyethylene glycol #400	4.0
Sodium carboxymethylcellulose	1.2
Sodium saccharin	0.2
Hexaglycerol monostearate	2.0
N--lauroyl glutamate	0.5
Flavor	1.0
Coloring agent	q.s.
Chlorohexidine gluconate	0.01
Purified water	Balance
Total	100.0

Example 2: Tooth paste

Formulation	%
Calcium carbonate (heavy)	30.0
Calcium carbonate (light)	15.0
Propylene glycol	3.0
Sorbitol liquid	30.0
Sodium carboxymethylcellulose	1.0
Sodium saccharin	0.1
Tranexamic acid	0.1
Decaglycerol monolaurate	1.0
N--lauroyl-N--methyl-.beta.-aranate	1.0
Flavor	1.0
Preservative	q.s.
Purified water	Balance
Total	100.0

Example 3: Tooth paste

Formulation	%
Dicalcium phosphate	50.0
Silica	3.0
Propylene glycol	2.0
Sorbitol liquid	25.0
Sodium carboxymethylcellulose	0.8
Carrageenan	0.3
Sodium saccharin	0.2
Hexaglycerol monomyristate	2.0

Sucrose monomyristate	1.0
Allantoin chlorohydroxy aluminum	0.1
Flavor	1.0
Preservative	q.s.
Purified water	Balance
Total	100.0

Example 4: Tooth paste

Formulation	%
Zirconosilicate	15.0
Silica	2.0
Polyethylene glycol #400	3.0
Sorbitol liquid	60.0
Sodium carboxymethylcellulose	1.4
Sodium saccharin	0.2
Decaglycerol monolaurate	1.5
N--myristoyl glutamate	1.0
.beta.-Glycyrrhezinic acid	0.01
Tocopherol acetate	0.1
Sodium fluoride	0.2
Flavor	1.0
Coloring agent	q.s.
Purified water	Balance
Total	100.0

Example 5: Tooth paste

Formulation	%
Aluminum hydroxide	35.0
Aluminum oxide	2.0
Propylene glycol	3.0
Sorbitol liquid	15.0
Glycerol	5.0
Sodium carboxymethylcellulose	1.2
Sodium saccharin	0.1
Sodium chloride	10.0
Decaglycerol monooleate	1.5
N--myristoyl sarcosinate	0.5
Isopropylmethyl phenol	0.05
Flavor	1.0
Purified water	Balance
Total	100.0

Example 6: Wet dentifrice

Formulation	%
Dicalcium phosphate	35.0
Calcium carbonate	40.0
Glycerol	10.0

Sodium carboxymethylcellulose	0.3
Sodium saccharin	0.2
Decaglycerol monolaurate	1.5
Flavor	1.5
Purified water	Balance
Total	100.0

Example 7: Mouth wash Formulation	%
Ethanol	10.0
Glycerol	10.0
Sorbitol liquid	5.0
Citric acid	0.1
Sodium citrate	0.4
Sodium saccharin	0.05
Hexaglycerol monolaurate	1.5
Flavor	1.0
Purified water	Balance
Total	100.0

L17 ANSWER 27 OF 33 USPATFULL
ACCESSION NUMBER: 89:71845 USPATFULL
TITLE: Pharmaceutical compositions
INVENTOR(S): Gottwald, Eberhard F., Bovenden, Germany, Federal Republic of
Machoczek, Horst M., Gleichen-Reinhausen, Germany, Federal Republic of
PATENT ASSIGNEE(S): Smith Kline Dauelsberg GmbH, Gottingen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4861592	19890829
APPLICATION INFO.:	US 1987-57578	19870602 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1985-744096, filed on 6 Jun 1985, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Waddell, Frederick E.
LEGAL REPRESENTATIVE: Marlino, Joseph A.; Suter, Stuart R.; Lourie, Alan D.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical composition suitable for oral adminstration comprising particulate cimetidine suspended in an aqueous phase containing a buffer which maintains the pH at greater than 7 and a suspending agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . water (2.01 g). When the mixture so obtained had formed a gel (after about 12 hours), a solution of 70% **sorbitol** (2.684 g), magnesium hydroxide (50 mg), **calcium carbonate** (500 mg), microcrystalline cellulose-sodium carboxymethylcellulose suspending

agent (200 mg, sold under the trade name Avicel RC 581), calcium arachinate (130 mg) potassium glycyrrhizinate (5 mg) and **cimetidine** (100 mg) were added with vigorous stirring. This suspension was passed through a vacuum degasser and mixed with a flavouring. . .

L17 ANSWER 28 OF 33 USPATFULL

ACCESSION NUMBER:	88:62330 USPATFULL
TITLE:	Oral composition
INVENTOR(S):	Gomi, Tetsuo, Tokyo, Japan Suganuma, Nobuo, Funabashi, Japan Ishii, Kazuo, Kawaguchi, Japan Sato, Hiroshi, Saitama, Japan
PATENT ASSIGNEE(S):	Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4774076	19880927
APPLICATION INFO.:	US 1986-934748	19861125 (6)
DISCLAIMER DATE:	20040310	
RELATED APPLN. INFO.:	Division of Ser. No. US 1983-509668, filed on 30 Jun 1983, now patented, Pat. No. US 4649044	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-114505	19820630

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Brown, J. R.
ASSISTANT EXAMINER:	Moezie, F. T.
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
LINE COUNT:	677

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In an oral composition comprising an amino compound, for example, tranexamic acid and .epsilon.-aminocaproic acid, a flavor, a surface-active agent, water, and optionally, a humectant, a binder, and an abrasive, the flavor is at least partially comprised of an aldehyde flavor compatible with the amino compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD

Calcium carbonate	40%
Silicic anhydride	3
Propylene glycol	3
Sorbitol	10
Glycerin	15
Stevioside	0.1%
Sodium lauryl sulfate	1.5
Sodium carboxymethyl cellulose	1.0
Tranexamic acid	2.0
Sodium chloride	10.0
Flavor mixture No. 8	1.2
Water	Balance
	100.0

L17 ANSWER 29 OF 33 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD

ACCESSION NUMBER: 1988-355373 [50] WPIDS
CROSS REFERENCE: 1988-316468 [45]; 1990-009109 [02]
DOC. NO. CPI: C1988-157090
TITLE: Pharmaceutical compsns. contg. cimetidine - with antacid in form of granules to overcome reduced bio availability.
DERWENT CLASS: A96 B03
INVENTOR(S): FRANCE, G; LEONARD, G S; PEARMAIN, K E
PATENT ASSIGNEE(S): (SMIK) SMITH KLINE FRENCH LAB
COUNTRY COUNT: 17
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 294933	A	19881214	(198850)*	EN	10
R: AT BE CH DE ES FR GB GR IT LI LU NL SE					
PT 90466	A	19891130	(199002)		
JP 01313420	A	19891218	(199005)		
ZA 8903224	A	19891227	(199006)		
ZA 8803167	A	19900228	(199013)		
EP 294933	B	19920311	(199211)		11
R: AT BE CH DE ES FR GB GR IT LI LU NL SE					
DE 3868986	G	19920416	(199217)		
ES 2032963	T3	19930301	(199321)		
IE 62728	B	19950222	(199519)		
JP 2635407	B2	19970730	(199735)		4

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 294933	A	EP 1988-304008	19880504
JP 01313420	A	JP 1989-111918	19890428
ZA 8903224	A	ZA 1989-3224	19890502
ZA 8803167	A	ZA 1988-3167	19880504
EP 294933	B	EP 1988-304008	19880504
ES 2032963	T3	EP 1988-304008	19880504
IE 62728	B	IE 1989-1414	19890501
JP 2635407	B2	JP 1989-111918	19890428

FILING DETAILS:

PATENT NO	KIND		PATENT NO
ES 2032963	T3	Based on	EP 294933
JP 2635407	B2	Previous Publ.	JP 01313420

PRIORITY APPLN. INFO: GB 1987-10965 19870508; EP 1988-304008 19880504; GB 1988-20265 19880826; EP 1989-304248 19890427; GB 1987-10966 19870508

AN 1988-355373 [50] WPIDS
CR 1988-316468 [45]; 1990-009109 [02]
AB EP 294933 A UPAB: 19940727
A solid pharmaceutical dosage form is claimed comprising (a) cimetidine and (b) antacid, where at least part of the antacid is in the form of granules comprising a freely water-soluble solid diluent, the antacid and a rapidly swellable water-insoluble disintegrant. The granules are also claimed. The solid diluent is pref. a sugar or a sugar alcohol. The disintegrant is pref. a cross-linked CMC.

Also claimed is a chewable pharmaceutical tablet compsn. comprising

(a) granules comprising **cimetidine** and a granulating agent comprising a copolymer of dimethylaminoethylmethacrylate and methacrylic acid ester in an amt. of 10 wt.% relative to the **cimetidine** and (b) **antacid**-contg. granules comprising Al(OH)3 and Mg(OH)2 a solid diluent which is lactose or a mixt. of **sorbitol** and lactose, the ratio (w/w) of diluent to Al(OH)3/Mg(OH)2 being 3:1 and a disintegrant which is croscarmellose sodium, the disintegrant being present in an amt. of 2 wt.% relative to the total wt. of the **antacid**-contg. granules, where the **antacid**-contg. granules are formed by dry granulation.

USE/ADVANTAGE - Cimetidine is a histamine H2-antagonist (see 1,397,436) useful in the treatment of duodenal, gastric, recurrent and stomal ulceration and reflux oesophagitis, etc.

Dwg.0/0

Dwg.0/0

ABEQ DE 3868986 G UPAB: 19930923

A solid pharmaceutical dosage form is claimed comprising (a) cimetidine and (b) antacid, where at least part of the antacid is in the form of granules comprising a freely water-soluble solid diluent, the antacid and a rapidly swellable water-insoluble disintegrant. The granules are also claimed. The solid diluent is pref. a sugar or a sugar alcohol. The disintegrant is pref. a cross-linked CMC.

Also claimed is a chewable pharmaceutical tablet compsn. comprising (a) granules comprising **cimetidine** and a granulating agent comprising a copolymer of dimethylaminoethylmethacrylate and methacrylic acid ester in an amt. of 10 wt.% relative to the **cimetidine** and (b) **antacid**-contg. granules comprising Al(OH)3 and Mg(OH)2 a solid diluent which is lactose or a mixt. of **sorbitol** and lactose, the ratio (w/w) of diluent to Al(OH)3/Mg(OH)2 being 3:1 and a disintegrant which is croscarmellose sodium, the disintegrant being present in an amt. of 2 wt.% relative to the total wt. of the **antacid**-contg. granules, where the **antacid**-contg. granules are formed by dry granulation.

USE/ADVANTAGE - Cimetidine is a histamine H2-antagonist (see 1,397,436) useful in the treatment of duodenal, gastric, recurrent and stomal ulceration and reflux oesophagitis, etc.

ABEQ EP 294933 B UPAB: 19930923

A solid pharmaceutical dosage from comprising: (i) cimetidine; and (ii) antacid, wherein at least 50% of the antacid is in the form of granules comprising a freely water-soluble solid diluent, the antacid, and a rapidly swellable water-insoluble disintegrant.

ABEQ EP 349103 B UPAB: 19930923

A pharmaceutical chewable tablet composition comprising: (i) granules containing a histamine H2-receptor antagonist; and (ii) an extragranular water-insoluble hygroscopic excipient in an amount of 5% to 15% by weight of the total weight of the tablet.

0/0

ABEQ US 5169640 A UPAB: 19930923

Solid dosage form comprises 50-800 mg cimetidine and 5-30 (14) mE1. antacid at least 50% of which is in granule form. The granules comprises a water-soluble solid diluent, the antacid and a rapidly swellable water-insol. disintegrant. The antacid is separately granulated from the cimetidine.

Pref. the solid diluent is a sugar or sugar alcohol in wt. ratio diluent:antacid 1:1 to 8:1. A pref. disintegrant is a crosslinked carboxymethylcellulose. Pref. the antacid is mixt. Al(OH)3 and Mg(OH)2. Pref. the dosage form is a chewable tablet with the cimetidine coated with 2-10% of its wt. of a copolymer of di-methylaminoethylmethacrylate and

methacrylic acid esters to mask the bitter taste.
USE - Combination of an anti-histamine and antacid combats G.I. ulcers and reflux oesophogitis without reducing the bioavailability of cimetidine.
0/0

ABEQ US 5188839 A UPAB: 19930923
Solid pharmaceutical dosage form comprising pharmaceutical granules comprise an effective amt. of cimetidine and about 2-20% w/w relative to the ametidine of a copolymer of dimethylaminoethyl methacrylate and neutral methacylic acid esters. The copolymer functions as a granulating and binding agent and is in admixture with the cimetidine. The granules are compresseed into a tablet. The copolymer is present in an amt. of 5-15
(10)% (w/w) w.r.t. the cimetidine. The dosage further comprises antacids and alignates.
USE/ADVANTAGE - The dosage form masks the bitter taste of cimetidine,
have good palatability and soln. characteristics.
0/0

AB . . .
alcohol. The disintegrant is pref. a cross-linked CMC.
Also claimed is a chewable pharmaceutical tablet compsn. comprising (a) granules comprising **cimetidine** and a granulating agent comprising a copolymer of dimethylaminoethylmethacrylate and methacrylic acid ester in an amt. of 10 wt.% relative to the **cimetidine** and (b) **antacid**-contg. granules comprising Al(OH)3 and Mg(OH)2 a solid diluent which is lactose or a mixt. of **sorbitol** and lactose, the ratio (w/w) of diluent to Al(OH)3/Mg(OH)2 being 3:1 and a disintegrant which is croscarmellose sodium, the disintegrant being present in an amt. of 2 wt.% relative to the total wt. of the **antacid**-contg. granules, where the **antacid**-contg. granules are formed by dry granulation.
USE/ADVANTAGE - Cimetidine is a histamine H2-antagonist (see 1,397,436) useful in the treatment of. . .

ABEQ. . .
The disintegrant is pref. a cross-linked CMC.
Also claimed is a chewable pharmaceutical tablet compsn. comprising (a) granules comprising **cimetidine** and a granulating agent comprising a copolymer of dimethylaminoethylmethacrylate and methacrylic acid ester in an amt. of 10 wt.% relative to the **cimetidine** and (b) **antacid**-contg. granules comprising Al(OH)3 and Mg(OH)2 a solid diluent which is lactose or a mixt. of **sorbitol** and lactose, the ratio (w/w) of diluent to Al(OH)3/Mg(OH)2 being 3:1 and a disintegrant which is croscarmellose sodium, the disintegrant being present in an amt. of 2 wt.% relative to the total wt. of the **antacid**-contg. granules, where the **antacid**-contg. granules are formed by dry granulation.
USE/ADVANTAGE - Cimetidine is a histamine H2-antagonist (see 1,397,436) useful in the treatment. . .

L17 ANSWER 30 OF 33 USPATFULL
ACCESSION NUMBER: 87:16864 USPATFULL
TITLE: Oral composition
INVENTOR(S): Gomi, Tetsuo, Tokyo, Japan
Suganuma, Nobuo, Funabashi, Japan
Ishii, Kazuo, Kawaguchi, Japan
Sato, Hiroshi, Saitama, Japan
PATENT ASSIGNEE(S): Lion Corporation, Tokyo, Japan (non-U.S. corporation)

NUMBER DATE

	NUMBER	DATE
PATENT INFORMATION:	US 4649044	19870310
APPLICATION INFO.:	US 1983-509668	19830630 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-114505	19820630

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch and Birch
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 661
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In an oral composition comprising an amino compound, for example, tranexamic acid and .epsilon.-aminocaproic acid, a flavor, a surface-active agent, water, and optionally, a humectant, a binder, and an abrasive, the flavor is at least partially comprised of an aldehyde flavor compatible with the amino compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD

Toothpaste

Calcium carbonate	40%
Silicic anhydride	3
Propylene glycol	3
Sorbitol	10
Glycerin	15
Stevioside	0.1%
Sodium lauryl sulfate	1.5
Sodium carboxymethyl cellulose	1.0
Tranexamic acid	2.0
Sodium chloride	10.0
Flavor mixture No. 8	1.2
Water	Balance
	100.0

L17 ANSWER 31 OF 33 USPATFULL
ACCESSION NUMBER: 85:23874 USPATFULL
TITLE: Oral compositions
INVENTOR(S): Komiyama, Noboru, Tokyo, Japan
Itoi, Hiroshi, Kamagaya, Japan
Sano, Hiroshi, Hachioji, Japan
PATENT ASSIGNEE(S): Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4512968	19850423
APPLICATION INFO.:	US 1983-555111	19831123 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1982-210817	19821130
	JP 1983-24853	19830218

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.

LEGAL REPRESENTATIVE: Flynn, Thiel, Boutell & Tanis
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chitin or chitin derivatives compounded with oral compositions such as dentifrice, mouth rinse, oral freshener, chewing gum and the like exhibit superior medicine effects for the prevention of dental caries, periodontoclasia and mouth odor. And, chitosan salt is also effective as the binding agent for use in the above mentioned oral compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD . . . chitin or chitin derivatives to be compounded. For instance, in the dentifrice there can be used humectants such as glycerine, **sorbitol**, propylene glycol and the like; abrasives such as calcium hydrogen phosphate, calcium pyrophosphate, **calcium carbonate**, aluminum hydroxide, hydrated silica, anhydrous silica, calcium sulfate, magnesium phosphate, calcium sulfite, zeolite, insoluble sodium metaphosphate and the like; binding. . . agents; perfumes such as menthol, anethole; sweetening materials; effective ingredients such as chlorhexidine hydrochloride, chlorhexidine gluconate, .epsilon.-amino caproic acid, dihydrocholestanol, **tranexamic acid**, allantoin, allantoin-chlorohydroxy aluminum, sodium monofluorophosphate, dextranase, polyethylene glycol, sodium chloride and the like; preservatives; water and the like. Similarly, the. . .

L17 ANSWER 32 OF 33 USPATFULL
ACCESSION NUMBER: 84:46874 USPATFULL
TITLE: Oral composition
INVENTOR(S): Ichikawa, Hiromichi, Matsudo, Japan
Saso, Kazuo, Hiratsuka, Japan
Suganuma, Nobuo, Funabashi, Japan
PATENT ASSIGNEE(S): Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 4466954	19840821	
APPLICATION INFO.:	US 1982-427542	19820929	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1981-213094	19811229

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A stable dextranase-containing oral composition having a good feeling upon use is disclosed which comprises a dextranase enzyme produced by the genus Chaetomium, one of fungi, and a stabilizing amount of an admixture comprising water-soluble salts of alkyl sulfates having 10, 12, 14, and 16 carbon atoms in the alkyl chain in the following proportion:

C.sub.10 --alkyl sulfate salt 0-20%,
C.sub.12 --alkyl sulfate salt 50-80%,
C.sub.14 --alkyl sulfate salt 10-30%, and
C.sub.16 --alkyl sulfate salt 0-15%,

based on the weight of the admixture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD

Ingredient	% by weight
Calcium carbonate	50
Propylene glycol	3
Sorbitol	30
Lauroyl sarcosinate	0.3
Sodium alkyl sulfates	0.8
Palmitoyl diethanol amide	1.0
Carrageenan	0.5
Sodium alginate	0.5
Tranexamic acid	0.1
Sodium monofluorophosphate	0.76
Flavor	1.0
Sodium saccharin	0.1
Dextranase (10.sup.6 units/g)	0.1
Water	Balance
	100.0%
Dextranase retentivity	.circle.
Taste	.circle.
Foaming	.circle.
Low-temperature extrusion	.circle.

L17 ANSWER 33 OF 33 USPATFULL

ACCESSION NUMBER: 84:45484 USPATFULL
TITLE: Oral compositions of tranexamic acid and carvone
INVENTOR(S): Sato, Hiroshi, Tokyo, Japan
Watanabe, Haruo, Higashikurume, Japan
Suganuma, Nobuo, Funabashi, Japan
PATENT ASSIGNEE(S): Lion Corporation, Tokyo, Japan (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 4465662	19840814	
APPLICATION INFO.:	US 1981-250221	19810402	(6)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1981-45823	19810408

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 535
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An oral composition containing tranexamic acid in which carvone is blended in an amount of 0.1 to 5% by weight and l-menthol may preferably be blended in an amount of 0.03 to 10% by weight. Carvone improves the bitterness inherent to the tranexamic acid-containing oral composition. The composition may preferably contain a mixed humectant of sorbitol and glycerin at a weight ratio of 1:9 to 6:4 and a binder, at least 60% by weight of the binder being an alkali metal salt of carboxymethyl cellulose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD

Calcium carbonate	70%
Sorbitol	3%
Glycerine	7%
Sodium saccharin	0.1%
Sodium lauryl sulfate	1.5%
Tranexamic acid	0.03%
Carvone	0.8%
l-menthol	0.2%
Water	Balance
	100.0%

=> fil stng
COST IN U.S. DOLLARS — SINCE FILE ENTRY: 89.12 — TOTAL SESSION: 157.04

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 13:21:29 ON 01 JUN 2001
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 25, 2001 (20010525/UP).

=>
=> fil home
COST IN U.S. DOLLARS — SINCE FILE ENTRY: 0.00 — TOTAL SESSION: 157.04

FULL ESTIMATED COST

FILE 'HOME' ENTERED AT 13:36:55 ON 01 JUN 2001

=> fil stng
COST IN U.S. DOLLARS — SINCE FILE ENTRY: 0.15 — TOTAL SESSION: 157.19

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 13:37:02 ON 01 JUN 2001